Cosmos Health (COSM) 10-K/A 18 Apr 19 2018 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Apr. 16, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	Cosmos Holdings Inc.
Entity Central Index Key	0001474167
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float		$ 13,305,030
Entity Common Stock, Shares Outstanding			24,880,306
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Ex Transition Period	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 864,343	$ 782,853
Accounts receivable, net	4,753,291	1,255,596
Accounts receivable - related party	189,760	171,392
Other investments	217,361
Inventory	3,202,767	3,093,521
Equity investment	2,500,000
Prepaid expenses and other current assets	1,662,579	1,482,192
Prepaid expenses and other current assets - related party	4,957,061	2,724,972
TOTAL CURRENT ASSETS	18,347,162	9,510,526
Property and equipment, net	1,425,632	114,567
Goodwill and intangible assets, net	296,767	41,994
Deferred tax assets	913
Other assets	624,479	1,008,579
TOTAL ASSETS	20,694,953	10,675,666
CURRENT LIABILITIES:
Accounts payable and accrued expenses	5,933,464	1,778,333
Accounts payable and accrued expenses - related party	139,556	387,847
Customer advances	1,067,200
Convertible notes payable, net of unamortized discount of $276,841 and $2,989,110, respectively	135,800	121,604
Notes payable, net of unamortized discount of $0 and $126,763, respectively	9,803,733	9,951,745
Notes payable - related party	1,793,437	97,979
Lines of credit	1,514,583
Loans payable - related party	1,775,251	7,213
Taxes payable		1,358,789
Other current liabilities	111,212
TOTAL CURRENT LIABILITIES	22,274,236	13,703,510
Share settled debt obligation	1,554,590
Other liabilities	183,577
TOTAL LIABILITIES	24,012,403	13,703,510
Commitments and Contingencies (see Note 14)
STOCKHOLDERS' DEFICIT:
Preferred stock, $0.001 par value; 100,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2018 and 2017, respectively
Common stock, $0.001 par value; 300,000,000 shares authorized; 13,878,772 and 12,825,393 shares issued and 13,705,082 and 12,666,704 outstanding as of December 31, 2018 and 2017, respectively	13,879	12,825
Additional paid-in capital	13,133,982	5,652,429
Accumulated other comprehensive income (loss)	32,828	(1,385,229)
Accumulated deficit	(16,272,645)	(7,211,987)
Treasury stock, 173,690 and 158,689 shares as of December 31, 2018 and 2017, respectively	(225,494)	(95,882)
TOTAL STOCKHOLDERS' (DEFICIT)	(3,317,450)	(3,027,844)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 20,694,953	$ 10,675,666

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
CURRENT LIABILITIES:
Convertible notes payeble, net of unamortized discount	$ 276,841	$ 2,989,110
Notes payable, net of unamortized discount	$ 0	$ 126,763
STOCKHOLDERS' DEFICIT:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	13,878,772	12,825,393
Common stock, shares, outstanding	13,705,082	12,666,704
Treasury Stock	173,690	158,689

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Consolidated Statements Of Operations And Comprehensive
REVENUE	$ 37,083,882	$ 30,013,379
COST OF REVENUE	34,675,242	28,057,111
GROSS PROFIT	2,408,640	1,956,267
OPERATING EXPENSES
General and administrative expenses	3,593,132	4,852,801
Depreciation and amortization expense	43,930	25,903
Impairment of goodwill		1,949,884
TOTAL OPERATING EXPENSES	3,637,062	6,828,588
LOSS FROM OPERATIONS	(1,228,422)	(4,872,321)
OTHER INCOME (EXPENSE)
Other income (expense)	19,078	(27,492)
Interest expense - related party	(264)	(2,592)
Interest expense	(967,824)	(748,474)
Non-cash interest expense	(5,839,581)	(886,483)
Forgiveness of debt	47,717
Gain on exchange of equity investments, and gain on change in fair value	2,500,000
Gain on sale of Amplerissimo	146,647
Loss on extinguishment of debt	(1,464,698)
Debt modification expense	(1,942,156)
Foreign currency transaction gain (loss)	(313,829)	330,395
TOTAL OTHER EXPENSE, NET	(7,814,910)	(1,334,646)
LOSS BEFORE INCOME TAXES	(9,043,332)	(6,206,967)
INCOME TAX EXPENSE	(17,326)	(2,801)
NET LOSS	(9,060,658)	(6,209,768)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustment, net	1,418,057	(334,766)
TOTAL COMPREHENSIVE LOSS	$ (7,642,601)	$ (6,544,534)
BASIC NET LOSS PER SHARE	$ (0.68)	$ (0.49)
DILUTED NET LOSS PER SHARE	$ (0.68)	$ (0.49)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
Basic	13,306,612	12,780,013
Diluted	13,306,612	12,780,013

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Treasury Stock	Accumulated Other Comprehensive Income (Loss)	Total
Beginning Balance, Shares at Dec. 31, 2016		12,587,053
Beginning Balance, Amount at Dec. 31, 2016		$ 12,587	$ 287,293	$ (1,002,219)		$ (1,050,463)	$ (1,752,802)
Foreign currency translation adjustment, net						(334,766)	(334,766)
Stock-based compensation			338,792				338,792
Sale of common stock and warrants, Shares		14,340
Sale of common stock and warrants, Amount		$ 14	91,766				91,780
Acquisition of subsidiary - Issuance of stock in connection with acquisition, Shares		170,000
Acquisition of subsidiary - Issuance of stock in connection with acquisition, Amount		$ 170	1,478,830				1,479,000
Issuance of stock for services, Shares		54,000
Issuance of stock for services, Amount		$ 54	401,746				401,800
Relative fair value of warrants issued with convertible debt			1,545,288				1,545,288
Beneficial conversion feature related to convertible notes payable			1,140,711				1,140,711
Fair value of warrants issued for services			368,003				368,003
Conversion of convertible notes and accrued interest to common stock, Amount
Purchase of treasury stock, Shares					(138,690)
Purchase of treasury stock, Amount					$ (1,387)		(1,387)
Purchase of treasury stock from officer, Amount					(94,495)		(94,495)
Net income				(6,209,768)			(6,209,768)
Ending Balance, Shares at Dec. 31, 2017		12,825,393			(138,690)
Ending Balance, Amount at Dec. 31, 2017		$ 12,825	5,652,429	(7,211,987)	$ (95,882)	(1,385,229)	(3,027,844)
Foreign currency translation adjustment, net						1,418,057	1,418,057
Issuance of common stock for the exercise of options, Shares
Issuance of common stock for the exercise of options, Amount
Stock-based compensation			242,002				242,002
Modification of debt			3,518,241				3,518,241
Contribution of capital by an officer
Sale of common stock and warrants, Shares
Sale of common stock and warrants, Amount
Acquisition of subsidiary - Issuance of stock in connection with acquisition, Amount
Issuance of stock for services, Shares
Issuance of stock for services, Amount
Relative fair value of warrants issued with convertible debt			910,078				910,078
Beneficial conversion feature related to convertible notes payable			934,922				934,922
Fair value of warrants issued for services			157,969				157,969
Conversion of convertible notes and accrued interest to common stock, Shares		1,053,364
Conversion of convertible notes and accrued interest to common stock, Amount		$ 1,053	1,718,342				1,719,395
Purchase of treasury stock, Shares
Purchase of treasury stock, Amount
Purchase of treasury stock from officer, Shares					(55,000)
Purchase of treasury stock from officer, Amount					$ (129,612)		(129,612)
Net income				(9,060,658)			(9,060,658)
Ending Balance, Shares at Dec. 31, 2018		13,878,757			(193,690)
Ending Balance, Amount at Dec. 31, 2018		$ 13,879	$ 13,133,982	$ (16,272,645)	$ (225,494)	$ 32,828	$ (3,317,450)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,060,658)	$ (6,209,768)
Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities:
Depreciation and amortization expense	43,930	25,903
Amortization of debt discounts	5,681,613	518,481
Gain on sale of subsidiary	(146,647)
Loss on extinguishment of debt	1,464,698
Gain on forgiveness of debt	(47,717)
Loss on debt modification	1,942,156
Stock-based compensation	242,002	338,792
Issuance of common stock for services		401,800
Fair value of warrants issued for services	157,969	368,003
Gain on exchange of equity investments, and gain on change in fair value	(2,500,000)
Loss on goodwill impairment		1,949,884
Changes in Assets and Liabilities:
Accounts receivable	483,820	(534,909)
Accounts receivable - related party	(18,368)	(171,392)
Inventory	1,431,012	(2,623,788)
Prepaid expenses	864,925	(669,713)
Prepaid expenses - related party	(2,232,089)	(2,709,449)
Other assets	846,322	(531,324)
Accounts payable and accrued expenses	(332,749)	496,450
Accounts payable and accrued expenses - related party	(296,974)	312,666
Customer advances	(125,400)
Other current liabilities	31,116
Taxes payable	64,885	278,223
Other liabilities	(49,152)
NET CASH USED IN OPERATING ACTIVITIES	(1,555,305)	(8,760,141)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(503,362)	(55,337)
Cash received from acquisition	307,590	40,858
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	(195,772)	(14,479)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of convertible note payable	(3,557,381)	(239,286)
Proceeds from convertible note payable	1,845,000	2,686,000
Payment of related party note payable	(18,330)	(84,755)
Proceeds from related party note payable	1,718,400
Payment of note payable	(1,259,804)	(487,476)
Proceeds from note payable	403,957	7,541,413
Payment of related party loan	(631,166)	(978,730)
Proceeds from related party loan	2,408,965	817,040
Payment of loans payable		(20,437)
Payment of lines of credit	(437,576)
Proceeds from lines of credit	41,700
Proceeds from issuance of share settled debt obligation	1,554,590
Sale of common stock and warrants		91,780
Purchase of treasury stock	(80,053)	(34,460)
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,988,302	9,291,089
Effect of exchange rate changes on cash	(155,735)	(450,206)
NET INCREASE IN CASH	81,490	66,263
CASH AT BEGINNING OF YEAR	782,853	716,590
CASH AT END OF YEAR	864,343	782,853
Supplemental Disclosure of Cash Flow Information
Cash paid during the period: Interest	299,946	130,531
Cash paid during the period: Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Issuance of common stock related to the acquisition of Decahedron		1,479,000
Issuance of note payable related to the acquisition of Cosmofarm	227,912
Reversal of proceeds due from noteholder due to repayment of note		24,044
Proceeds due from sale of subsidiary	5,811
Pre-delivery shares issued for future conversion of convertible notes payable	1,054
Related party accrual for repurchase of shares of common stock	48,683	61,422
Discounts related to warrants issued with convertible debentures	910,078	1,545,288
Discounts related to beneficial conversion features of convertible debentures	934,922	1,140,711
Conversion of convertible notes and accrued interest to common stock, Amount	$ 1,719,395

ORGANIZATION AND NATURE OF BUSI

ORGANIZATION AND NATURE OF BUSINESS	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 1 - ORGANIZATION AND NATURE OF BUSINESS	Cosmos Holdings, Inc. (“us,” “we,” or the “Company”) is an international pharmaceutical wholesaler. The Company imports, exports and distributes pharmaceutical products of brand-name and generic pharmaceuticals, over-the-counter (OTC) medicines, a variety of vitamins, and dietary supplements. Currently, the Company distributes products mainly in the European Union (“EU”) countries via its three wholly owned subsidiaries Skypharm SA, Decahedron Ltd. and Cosmfarm Ltd. SkyPharm and Cosmofarm operates from facilities in Greece and Decahedron from its facilities in the UK. Most of our business derives from purchasing and reselling branded pharmaceutical products. Within the EU, large pharmaceutical manufacturers have variable pricing strategies. The varying prices allows us to source products produced by multi-national pharmaceutical companies in different countries throughout Europe and export them into countries that pay more for those products. The European pharmaceutical import/export market helps reduce prescription drugs costs. We are currently focusing our existing operations on expanding the business of SkyPharm, Decahedron and Cosmofarm. The Company’s focus is on branded pharmaceuticals, OTC medicines, and generic pharmaceuticals. However, the Company has also begun to expand into the food supplements industry and has already created its own line of vitamins and food supplement products. The Company plans to also expand its operations into the cosmetic/beauty industry. Through the sale of pharmaceutical products, the Company has created a wide network of pharmaceutical wholesalers and pharmacies that we believe we can utilize to promote and sell our vitamins, food supplements and cosmetic/beauty products. There is growing demand for various food supplements and other cosmetic and beauty products and we plan to serve this demand by offering quality products to our existing network of wholesalers and pharmacies. Pharmacies are still the key channels for distribution and sales of food supplements in the European market. In addition, we plan to expand into the full-line wholesale distribution business through acquisitions. Full-line pharmaceutical wholesalers provide the local markets with branded pharmaceuticals, generic pharmaceuticals, OTC medicines, vitamins, and food supplements. By expanding our pharmaceutical distribution business, we will have the ability to source branded and generic products directly from manufacturers and sell vitamins, food supplements, and cosmetic products directly to pharmacies that the full-line wholesaler currently sells to. We expect this expansion to increase our sales and profit margins as we vertically integrate into the supply chain. Concerning our vitamins and food supplement division, we have expanded our business in developing our own brand of vitamins and food supplements. The brand name of our product line is Sky Life Premium. We will bring these products to market though the network of wholesalers and pharmacies that we currently work with. Our current business has provided us with access to wholesalers both from the sourcing and the sales division of our wholesale business. We intend to sell our products to vendors that supply us with pharmaceutical products as well as to our clients that we currently sell pharmaceutical products to. We are also closely monitoring the legal framework for prescription and non-prescription derivates of cannabis products as it develops in Europe. As the legal framework and processes are developed and implemented in each respective EU country, we will utilize our existing network to distribute both prescription and non-prescription derivates of cannabis products to our current customer base. We currently intend to only distribute prescription and non-prescription derivates of cannabis products to approved EU countries and not in the US. We regularly evaluate acquisition targets that would allow us to expand our distribution reach and/or vertically integrate into the supply chain of the products that we currently distribute. We believe that the demand for reasonably-priced medicines, delivered on time and in the highest quality is set to increase in the years to come, as the population’s life expectancy increases. With our product portfolio of patented and non-patented medicines, we contribute to the optimization of efficient medicinal care, and thereby lowering cost for health insurance funds, companies, and patients. We also believe that the demand for non-prescription wellness products such as food and dietary supplements will continue to increase as individuals are increasingly supplementing their nutritional intake. We believe the EU pharmaceutical import/export market will continue to grow. We continue to encounter competition in the market as we grow. The competition comes in the form of level of service, reliability, and product quality. On the procurement side we continue to expand our vendor base. In order to minimize business risks, we diversify our sources of supply. We maintain our high-quality standards by carefully selecting and qualifying our suppliers as well as actively ensuring that our suppliers meet our standard of quality control on an ongoing basis. As of July 22, 2015, the Hellenic Ministry of Health and more specifically the National Organization for Medicines granted to SkyPharm a license for the wholesale of pharmaceutical products for human use. The license is valid for a period of five years and pursuant to the EU directive of (2013/C343/02). SkyPharm is subject to the Guidelines of the Good Distribution Practices of the European Union (the “Good Distribution Practices”) for the sale and distribution of medical products for human use. SkyPharm believes it has properly incorporated all the methodologies, procedures, processes and resources in order to be in accordance with the guidelines of the Good Distribution Practices. Our warehouse has been equipped with the proper equipment, specifically with the proper shelves, working tables, medicines, cold fridge and barcode machines to comply with all requirements. In addition, our headquarters have also been equipped with the proper office equipment, specifically with the bureau tables, chairs and the terminals for each one working station, as well as central hardware systems (Servers) and software programs (ERP & CRM platforms) that are essential for the efficient running of the business are already installed and in place. The Company commenced sales of pharmaceutical products in the beginning of November 2015. Decahedron received its Wholesale Distribution Authorization for human use on November 7, 2013, from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in accordance with Regulation 18 of the Human Medicines Regulations 2012 (SI 2012/1916) and it is subject to the provision of those Regulations and the Medicines Act 1971. This license will continue to remain in force from the date of issue by the Licensing Authority unless cancelled, suspended, revoked or varied as to the period of its validity or relinquished by the authorization holder. Corporate History and Structure Cosmos Holdings, Inc. was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009. On November 14, 2013, we changed our name to Cosmos Holdings Inc. On September 27, 2013, the Company, closed a reverse take-over transaction by which it acquired a private company whose principal activities are the trading of products, providing representation, and provision of consulting services to various sectors. Pursuant to a Share Exchange Agreement between the Registrant and Amplerissimo Ltd, a company incorporated in Cyprus (“Amplerissimo”), the Company acquired 100% of Amplerissimo’s issued and outstanding common stock. As a result of the reverse take-over transaction, Amplerissimo became a wholly-owned subsidiary of the Company. On August 1, 2014, the Company, through its Cypriot subsidiary Amplerissimo, formed SkyPharm S.A., a Greek corporation (“SkyPharm”), a subsidiary that focuses on the trading, sourcing and distribution of pharmaceutical products. In February 2017, the Company completed the acquisition of Decahedron Ltd, a UK corporation (“Decahedron”) consummating the transactions contemplated by the Stock Purchase Agreement, dated November 17, 2016 as amended (the “Decahedron SPA”). Pursuant to the terms of the Decahedron SPA, the shareholders of Decahedron received an aggregate of 170,000 shares of common stock of the Company (the “Stock Consideration”), which were delivered following the closing in exchange for all of the ordinary shares of Decahedron for the stock consideration. Decahedron is a fully licensed wholesaler of pharmaceutical products and its primary activity is the distribution, import and export of pharmaceuticals. In accordance with the terms of the SPA, the principal and majority shareholder of Decahedron, Nicholas Lazarou, remained as a director and officer of Decahedron. On November 21, 2017, the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, and warrants including all share and per-share data, for all amounts and periods presented in the consolidated financial statements. On September 29, 2018, Amplerissimo transferred its remaining 22% investment in SkyPharm to the Company. The Company now holds 100% of the capital of SkyPharm and SkyPharm remains a 100% wholly owned subsidiary of the Company. On September 30, 2018, the Company entered into a Share Purchase Agreement “SPA” with an unaffiliated third party. The Company sold 100% of the issued capital of its subsidiary, Amplerissimo. On December 19, 2018, the Company completed the purchase of all of the capital stock of Cosmofarm Ltd., a pharmaceutical wholesaler based in Athens, Greece. The principal of the selling shareholder is Panagiotis Kozaris, who remained with Cosmofarm as a director and chief operating officer once it became a wholly-owned subsidiary of the Company. Grigorios Siokas, the Company’s CEO, became the new CEO of Cosmofarm. Mr. Kozaris had no prior relationship to the Company other than as an independent shareholder. The purchase price payable is €200,000 evidenced by a promissory note. The Company had $37,083,882 in total revenues and expended $34,675,242 for the year ended December 31, 2018, in connection with these operations. Going Concern The Company's consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company generated a net loss of $9,060,658 for the year ended December 31, 2018 and has a working capital deficit of $3,927,074 and an accumulated deficit of $16,272,645 as of December 31, 2018. These conditions raise substantial doubt of the Company’s ability to continue as a going concern. The Company has not yet established an adequate ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease development of operations. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management's plans to continue as a going concern include raising additional capital through increased sales of product and by sale of common shares. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Summary of Significant Accounting Policies Basis of Financial Statement Presentation The accompanying consolidated financial statements have been prepared in accordance with principles generally accepted in the United States of America. Principles of Consolidation Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, SkyPharm S.A., Decahedron Ltd. and Cosmofarm Ltd. All significant intercompany balances and transactions have been eliminated. Use of Estimates The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2018 and December 31, 2017, there were no cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars and in the Republic of Cyprus, in Greece and in Bulgaria all of which are denominated in Euros. Additionally, the Company maintains a bank account in the United Kingdom denominated in British Pounds. For the year ended December 31, 2018, the amounts in these accounts were $242,903, $203,806 (the Euro equivalent of which was €177,903) and $119,357 (the British Pound equivalent of which was £93,872). At December 31, 2017, the amounts in these accounts were $65,613, $398,841 (the Euro equivalent of which was €331,759) and $27,542 (the British Pound equivalent of which was £20,358). Additionally, for the years ended December 31, 2018 and 2017, the Company had cash on hand in the amount of $166,350 and $290,857, respectively. Accounts Receivable Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. At December 31, 2018 and 2017, the Company's allowance for doubtful accounts was $540,048 and $0, respectively. Tax Receivables The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of December 31, 2018 and 2017, the Company had a VAT net receivable balance of $729,790 and $961,220 respectively, recorded in the consolidated balance sheet as other assets. Inventory Inventory is stated at the lower of cost or net realizable value using the weighted average cost method. Inventory consists primarily of finished goods and packaging materials, i.e. packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment. The Company writes-down inventories to net realizable value based on physical condition, expiration date, current market conditions, as well as forecasted demand. The Company’s inventories are not highly susceptible to obsolescence. Many of the Company’s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met. Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is provided on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Leasehold improvements and technical works 40 years Vehicles 6-20 years Machinery 20 years Furniture, fixtures and equipment 5–10 years Computers and software 3-5 years Depreciation expense was $34,623 and $17,370 for the years ended December 31, 2018 and December 31, 2017, respectively. Intangible Assets Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. At December 31, 2018, no revision to the remaining amortization period of the intangible assets was made. Amortization expense was $9,307 and $8,533 for the years ended December 31, 2018 and 2017, respectively. Impairment of Long-Lived Assets In accordance with Accounting Standards Codification (“ASC”) 360-10, long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Goodwill and Intangibles The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. Prior to the acquisition of Decahedron, the Company had no recorded goodwill. As a result of the acquisition of Decahedron, the Company tested and impaired 100% of the goodwill allocated to the acquisition costs, an amount equal to $1,949,884 for the year ended December 31, 2017. On December 19, 2018 as a result of the acquisition of Cosmofarm, the Company recorded $49,697 of goodwill. The Company tested the goodwill acquired and determined that no impairment was required as of December 31, 2018. Equity Method Investment For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company records its share in the earnings of the investee and is included in “Equity earnings of affiliate” in the consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value. Investments in Equity Securities Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01, and accordingly, investments in equity securities are accounted for at fair value with changes in fair value recognized in income from operations. Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for use in current operations are reported as a component of current assets in the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets in the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment. Investments consisted of 40,000 shares which traded at a closing price of $5.27, or value of $210,790 of Diversa S.A. and 16,666 share which traded at a closing price of $0.13 or value of $2,100 of National Bank of Greece. Additionally, the Company has $4,470 in equity securities of Pancreta bank, which are not publicly traded and recorded at cost. See note 5 for additional investments in equity securities. Fair Value Measurement The Company applied FASB ASC 820-Fair Value Measurements and Disclosures, or ASC 820, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The following table presents assets that are measured and recognized at fair value as of December 31, 2018, on a recurring basis: December 31, 2018 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities – ICC International Cannabis Corp. $ 2,500,000 - - $ 2,500,000 Marketable securities – Divsersa S.A. 210,790 - - 210,790 Marketable securities – National Bank of Greece 2,100 - - 2,100 $ 2,712,890 $ 2,712,890 The Company did not have any Level 2 or Level 3 assets or liabilities as of December 31, 2018. FASB ASC 825-10-25 Fair Value Option, or ASC 825-10-25, was effective for January 1, 2008. ASC 825-10-25 expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments. Revenue Recognition The Company adopted the modified retrospective adoption in accordance with ASC 606 – Revenue from Contracts with Customers, on January 1, 2018. The new guidance introduces a five-step model for recognizing revenue by applying the following steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligations are satisfied by transferring the promised goods to the customer. Once these steps are met, revenue is recognized upon delivery of the product. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements. Stock-based Compensation The Company records stock-based compensation in accordance with ASC section 718, "Stock Compensation" and Staff Accounting Bulletin (SAB) No. 107 (SAB 107) issued by the SEC in March 2005 regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Merton Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 505-50 "Equity-Based Payments to Non-Employees". Foreign Currency Translations and Transactions Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders' equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity's local currency) are included in net earnings. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash investments and accounts receivable. The following tables show the number of the Company's clients which contributed 10% or more of revenue and accounts receivable, respectively: Year Ended December 31, Year Ended December 31, 2018 2017 Number of 10% clients 2 3 Percentage of total revenue 26.49 % 49.63 % Percentage of total AR 4.94 % 20.68 % Income Taxes The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company is liable for income taxes in Greece and the United Kingdom of England. The corporate income tax rate is 29% in Greece (tax losses are carried forward for five years effective January 1, 2013) and 20% in United Kingdom of England. Losses may also be subject to limitation under certain rules regarding change of ownership. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At December 31, 2018 the Company has maintained a valuation allowance against all net deferred tax assets in each jurisdiction in which it is subject to income tax. The Company periodically reviews the uncertainties and judgments related to the application of complex income tax regulations to determine income tax liabilities in several jurisdictions. The Company uses a “more likely than not” criterion for recognizing the income tax benefit of uncertain tax positions and establishing measurement criteria for income tax benefits. The Company has evaluated the impact of these positions and due to the fact that the fiscal years 2013 - 2014 are unaudited by the Greek tax authorities, a potential tax liability has been identified, which may arise from a prospective tax audit from tax authorities, based on the tax settlement note of years 2007 - 2009. The amount of the liability as of December 31, 2018, was $145,504, and has been recorded as a long-term liability within the balance sheet. Retirement and Termination Benefits Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee’s work experience and renumeration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same d

ACQUISITION OF DECAHEDRON, LTD.

ACQUISITION OF DECAHEDRON, LTD.	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 2 - ACQUISITION OF DECAHEDRON, LTD.	On February 10, 2017, the Company completed the acquisition pursuant to the Decahedron SPA acquiring 100% of the outstanding shares of Decahedron, a United Kingdom company. Decahedron is a pharmaceuticals wholesaler which specializes in imports and exports of branded and generic pharmaceutical products within the EU and around the world. At closing, the Company acquired 100% of Decahedron’s outstanding shares and in exchange for 170,000 shares of Cosmos common stock valued at $1,479,000 (the “Acquisition”). The Company recognized cash of $40,858 acquired in the acquisition. The Company recognized the remaining Decahedron assets acquired and liabilities assumed based upon the fair value of such assets and liabilities measured as of the date of acquisition. The aggregate purchase price for Decahedron has been allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as capitalizable intangible assets, such as the license held by Decahedron for the wholesale of pharmaceuticals in the United Kingdom and Europe, the remainder has been allocated to goodwill, none of which is tax deductible. During the year ended December 31, 2017, we recorded an adjustment of $28,002 primarily related to other assets and an adjustment of the accounts payable associated with the Decahedron acquisition. We finalized our allocation of the purchase price during the year ended December 31, 2017. The final allocation of the purchase price as of December 31, 2017, is as follows: Preliminary Allocation as of February 10, Allocation Final 2017 Adjustments Allocation Current assets $ 6,537 $ - $ 6,537 Intangible assets 50,000 - 50,000 Other assets 305,400 (216,562 ) 88,838 Total assets acquired 361,937 (216,562 ) 145,375 Liabilities assumed: Debt 804,819 (188,560 ) 616,259 Total liabilities assumed 804,819 (188,560 ) 616,259 Net assets acquired (442,882 ) (28,002 ) (470,884 ) Consideration: Value of Common Stock Issued at Acquisition 1,479,000 - 1,479,000 Goodwill $ 1,921,882 $ 28,002 $ 1,949,884 The components of the acquired intangible assets were as follows (in thousands): Amount Useful Life (Years) Licenses (a) $ 50,000 5 $ 50,000 - _____________ (a) U.K Pharmaceutical Wholesale Distribution License Unaudited Supplemental Pro Forma Data The unaudited pro forma statements of operations data for the year ended December 31, 2018 and 2017, below, give effect to the Decahedron Acquisition, described above, as if it had occurred at January 1, 2016. These amounts have been calculated after applying our accounting policies and adjusting the results of Decahedron intangible amortization that would have been charged assuming the fair value adjustments had been applied and incurred since January 1, 2016. This pro forma data is presented for informational purposes only and does not purport to be indicative of our future results of operations. Revenue of $4,221,751 and net loss of $441,553 since the acquisition date are included in the consolidated statement of operations and comprehensive income (loss) for year ended December 31, 2017. Unaudited pro forma results of operations for the year ended December 31, 2018 and 2017 as though the Company acquired Decahedron on the first of each fiscal year are set forth below. Years Ended December 31, 2018 2017 Revenues $ 37,083,882 $ 30,206,825 Cost of revenues 34,675,242 28,256,544 Gross profit 2,408,640 1,950,281 Operating expenses 3,637,062 6,856,585 Operating loss (1,228,422 ) (4,906,304 ) Other income (expense) (7,814,910 ) (1,372,288 ) Income tax (expense) (17,326 ) (2,801 ) Net Loss $ (9,060,658 ) $ (6,281,393 ) Other comprehensive gain (loss) 1,418,018 (343,766 ) Comprehensive net loss $ (7,642,601 ) $ (6,616,159 ) The purchase price exceeded the estimated fair value of the net assets acquired by $1,949,884 which was recorded as Goodwill. Goodwill represents the difference between the total purchase price for the net assets purchased from Decahedron and the aggregate fair values of tangible and intangible assets acquired, less liabilities assumed. At the conclusion of the acquisition, goodwill was reviewed for impairment and it was determined that indicators of impairment existed. As of December 31, 2017, after our assessment of the totality of the events that could impair goodwill, it was the Company’s conclusion “it is more likely than not” that the Goodwill was impaired. As a result of the Company’s assessment, 100% of the goodwill of $1,949,884 was recorded as an impairment of goodwill.

ACQUISITION OF COSMOFARM, LTD.

ACQUISITION OF COSMOFARM, LTD.	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 3 - ACQUISITION OF COSMOFARM, LTD.	On December 19, 2018, the Company completed the acquisition pursuant to the Cosmofarm SPA acquiring 100% of the outstanding shares of Cosmofarm, a pharmaceutical wholesaler based in Athens, Greece. Cosmofarm is a fully licensed wholesaler of pharmaceutical products and its primary activity is the sourcing, procuring, and distributing branded and generic medicines, over-the-counter (OTC) pharmaceuticals, food supplements, and medical devices. At closing, the Company acquired 100% of Cosmofarm’s outstanding shares and in exchange for a non-interest-bearing promissory note, due in one-year, in the amount of €200,000 (the “Acquisition”). The Company recognized cash of $307,590 acquired in acquisition. The Company recognized the remaining Cosmofarm assets acquired and liabilities assumed based upon the fair value of such assets and liabilities measured as of the date of acquisition. The aggregate purchase price for Cosmofarm has been allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price over the fair value of the acquired net assets represent non-capitalizable intangible assets, such Cosmofarm’s tradename and customer base. The remainder of the excess has been allocated to goodwill. The allocation of the purchase price of Cosmofarm as of December 31, 2018, is as follows: Allocation Current assets $ 6,882,286 Intangible assets 213,790 Other assets 1,519,345 Total assets acquired 8,615,421 Liabilities assumed: Accounts payable and other current liabilities 5,111,489 Advances from customers 1,192,600 Line of credit 1,900,388 Other liabilities 232,729 Total liabilities assumed 8,437,206 Net assets acquired 178,215 Consideration: Promissory note 227,912 Goodwill $ 49,697 The components of the acquired intangible assets were as follows: Amount Useful Life (Years) Trademark $ 36,997 5 Customer base 176,793 10 $ 213,790 -

PREPAID FINANCING COSTS

PREPAID FINANCING COSTS	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 4 - PREPAID FINANCING COSTS	Papadopoulos, the director of Synthesis Peer-to-Peer Income Fund and CEO of Synthesis-Structured Commodity Trade Finance Limited, (See Note 13) and to two funds controlled by Mr. Spyros Papadopoulos. More specifically, the Company paid directly to Mr. Spyros Papadopoulos a total of €587,293 ($706,044), to Synthesis Management a total of €178,293 ($214,344), and to Synthesis Multi-Asset Architecture SICAV-SIF a total of €180,840 ($217,406) for advisory fees for the Company’s financing. The Company and Mr. Spyros Papadopoulos are negotiating an advisory consulting agreement, but no agreement has been executed as of the date of this filing. During the year ended December 31, 2017, the Company fully expensed the costs and the balance of the prepaid financing costs as of December 31, 2017, is $0.

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 5 - INVESTMENTS	Distribution and Equity Agreement On March 19, 2018, the Company entered into a Distribution and Equity Acquisition Agreement (the “Distribution and Equity Acquisition Agreement”) with Marathon Global Inc. (“Marathon”), a company incorporated in the Province of Ontario, Canada. Marathon was formed to be a global supplier of cannabis, cannabidiol (CBD) and/or any cannabis extract products, extracts, ancillaries and derivatives (collectively, the “Products”). The Company was appointed the exclusive distributor of the Products initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. The Company has no present intention to distribute any Products under this Agreement in the United States or otherwise participate in cannabis operations in the United States. The Company intends to await further clarification from the U.S. Government on cannabis regulation prior to determining whether to enter the domestic market. The Distribution and Equity Acquisition Agreement is to remain in effect indefinitely unless Marathon fails to provide Market Competitive (as defined) product pricing and Marathon has not become profitable within five (5) years of the agreement. The transaction closed on May 22, 2018 after the due diligence period, following which the Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. The Company was also given the right to nominate one director to the Marathon board of directors. Since Marathon is a newly formed entity with no assets and no activity, the Company attributed no value to the 5 million shares in Marathon which was received as consideration for the distribution services. As described below, the Company exchanged the Marathon shares in May and July 2018. Share Exchange Agreements On May 17, 2018, the Company entered into a Share Exchange Agreement (the “SEA”) with Marathon, ICC International Cannabis Corp (“ICC”) formerly known as Kaneh Bosm Biotechnology Inc. (“KBB”) and certain other sellers of Marathon capital stock. Under the SEA, the Company transferred 2.5 million shares in Marathon to ICC, a corporation incorporated under the laws of the Province of British Columbia and a public reporting issuer on the Canadian Securities Exchange, in exchange for 5 million shares of ICC. The Company accounted for the exchange at fair value and recognized a gain on exchange of its investment in Marathon of $1,953,000 included in “Gains on exchange of equity investments” in the consolidated statements of operations. On July 16, 2018, the Company completed a Share Exchange Agreement (the “New SEA”) with Marathon, ICC, and certain other sellers of Marathon capital stock whereby the Company transferred its remaining one-half interest (2.5 million shares) in Marathon to KBB for an additional 5 million shares of ICC. The Company accounted for the exchange at fair value and recognized a gain on exchange of its investment in Marathon of $2,092,200 included in Gains on exchange of equity investments in the consolidated statements of operations. The ten million shares of ICC owned by the Company constitute approximately 7% of the 141,219,108 shares of capital stock of KBB then issued and outstanding. The Company does not have the ability to exercise significant influence over ICC. The Company determined the fair value of both exchanges based on an actively quoted stock price of ICC received in exchange for the Marathon shares. The Company continues to fair value its investment in ICC with changes recognized in earnings each period and recorded an unrealized loss on exchange of investment during the year ended December 31, 2018 of $1,545,200 such that the net gain at the end of the period is $2,500,000. Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services, the Company would receive variable consideration in future for its services under the Distribution and Equity Acquisition Agreement, if certain milestones are achieved. Refer to Note 9 for the accounting associated with the cash of CAD $2 million received upfront. Variable consideration to be received in the future upon achieving the gross sales milestones described above, is constrained as the Company estimates that it is probable that a significant reversal of revenue could occur. In assessing the constraint, the Company considered its limited experience with the Products, new geographic markets and similar transactions, which affect the Company’s ability to estimate the likelihood of a probable revenue reversal. Therefore, no revenue has been recognized for the period ended December 31, 2018. The Company will continue to reassess variable consideration at each reporting period and update the transaction price when it becomes probable that a significant revenue reversal would not occur.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 6 - PROPERTY, PLANT AND EQUIPMENT	Property, plant and equipment, net consists of the following at December 31: 2018 2017 Leasehold Improvements $ 369,437 $ 3,098 Equipment under capital lease 709,356 - Vehicles 117,402 3,805 Furniture, fixtures and equipment 458,442 107,520 Computers and software 55,169 20,072 1,709,806 134,495 Less: Accumulated depreciation (284,174 ) (19,928 ) Total $ 1,425,632 $ 114,567 Property and equipment includes $193,034 of machinery and equipment financed through leasing arrangements (capital leases) at December 31, 2018. Accumulated amortization of assets under capital leases was $38,607 and $0 as of December 31, 2018 and 2017, respectively.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 7 - INTANGIBLE ASSETS	Intangible assets consist of the following at December 31,: 2018 2017 License $ 50,000 $ 50,000 Trade Name / Mark 36,997 - Customer Base 124,686 - 211,683 50,000 Less: Accumulated Amortization (16,720 ) (8,006 ) Total $ 194,963 $ 41,994

CAPITAL STRUCTURE

CAPITAL STRUCTURE	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 8 - CAPITAL STRUCTURE	Sale of Amplerissimo On September 29, 2018, Amplerissimo transferred its remaining 22% investment in SkyPharm to the Company for a purchase price of €2,200 ($2,528). The Company now holds 100% of the capital of SkyPharm. During the third quarter of fiscal 2018, management approved a plan to sell its Amplerissimo and its information technology business. Amplerissimo generated revenue of €5,747,947 ($7,639,022) in fiscal 2014 through agreements with two clients. These agreements have ten-year terms, with one having commenced on January 13, 2013, and another having commenced on May 14, 2013. As a result of the strong growth of our pharmaceutical business, Amplerissimo’s business has not been a priority for Cosmos and the Company has not pursued the continuation of further significant business activities in Amplerissimo after fiscal 2015. On September 30, 2018, the Company entered into a Share Purchase Agreement “SPA” with an unaffiliated third party. The Company sold 100% of the issued capital of its subsidiary, Amplerissimo, for a purchase price of €5,000 ($5,811), which was paid on October 12, 2018. The Company has recorded a gain on the sale of Amplerissimo of $146,647. A summary of the assets and liabilities that were disposed of in the sale of Amplerissimo is provided below: December 31, 2018 Cash and cash equivalents $ 683 Accounts receivable 13,421 Accounts payable and accrued expenses (8,775 ) Loans payable - related party (9,501 ) Taxes payable (1,423,674 ) Accumulated other comprehensive loss 1,287,010 Total liabilities extinguished (140,836 ) Proceeds due from sale of subsidiary (5,811 ) Gain on sale of Amplerissimo $ (146,647 ) Reverse Stock Split On November 21, 2017, the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, and warrants including all share and per-share data, for all amounts and periods presented in the consolidated financial statements. Preferred Stock The Company is authorized to issue 100 million shares of preferred stock, which have liquidation preference over the common stock and are non-voting. As of December 31, 2018 and December 31, 2017, no preferred shares have been issued. Common Stock The Company is authorized to issue 300 million shares of common stock and had issued 10,000,000 in connection with the merger and had 2,558,553 shares issued prior to the merger with Amplerissimo. On February 10, 2017, the Company and Decahedron consummated the acquisition of Decahedron SPA. Pursuant to the terms of the Decahedron SPA, the shareholders of Decahedron received an aggregate of 170,000 shares of common stock of the Company, which were delivered at closing in exchange for all of the Ordinary Shares of Decahedron for the stock consideration. Purchase of Treasury Shares Effective October 2, 2017, the Company entered into to a stock purchase agreement dated September 30, 2017, whereby for consideration of $1,387 the Company purchased 138,689 shares of its common stock from a third-party investor. The shares were transferred to the Company on October 17, 2017 and will be held in treasury. On December 19, 2017, the Company entered into a stock purchase agreement with an officer and director of the Company, whereby for consideration of €80,000 ($94,495) the Company will repurchase 20,000 shares of its common stock. As per the agreement, the sale and transfer of the shares occurred on December 19, 2017, the date of signing, however the Company is entitled to pay the full consideration in tranches until July 2018. As of December 31, 2017, the Company paid consideration of €28,000 ($33,073) and had an amount due to related party of €52,000 ($61,422). The shares were returned to the Company in February 2018. During the year ended December 31, 2018, the Company repaid the remaining balance of €52,000 ($63,446). The Company recorded a gain of $2,024 for the change in foreign currency related to this transaction. On June 18, 2018, the Company entered into a stock purchase agreement with an officer and director of the Company, whereby for consideration of €60,000 ($69,612) the Company repurchased 15,000 shares of its common stock. As per the agreement, the sale and transfer of the shares occurred on June 18, 2018, the date of signing, however the Company is entitled to pay the full consideration in tranches until November 2018. During the year ended December 31, 2018, the Company paid consideration of €60,000 ($69,178). The Company recorded a loss of $434 for the change in foreign currency related to this transaction. On November 30, 2018, the Company entered into a stock purchase agreement with an officer and director of the Company, whereby for consideration of $60,000, the Company repurchased 20,000 shares of its common stock. As per the agreement, the sale and transfer of the shares occurred on November 30, 2018, the date of signing, however the Company is entitled to pay the full consideration in tranches until August 2019. During the year ended December 31, 2018, the Company paid consideration of $11,317 and had a related party payable of $48,683. Shares Issued for Services On March 1, 2017, the Company entered into a four-month consulting agreement with a third-party investment advisory firm for consideration of 500 restricted shares of common stock to be issued during the period of the agreement for any introductions and related contributions the Company receives as a result of those introductions. As of December 31, 2017, no consideration has been earned and no shares have been issued related to this agreement and the agreement expired in accordance with its original terms. On May 1, 2017, the Company entered into an 8-month consulting agreement with a third party for web design services commencing on May 1, 2017 and terminating on January 1, 2018. As compensation for creating, delivering and maintaining a website, the Company issued 2,000 shares of common stock on May 24, 2017. The shares were valued at $14,400, which was fully recognized in the year ended December 31, 2017. On May 1, 2017, the Company entered into a five-month consulting agreement with a third-party advisory firm for consideration of 2,000 shares of the Company’s common stock. The stock was issued on May 25, 2017 and fair valued at $7.20 per share or $14,400, which was fully recognized in the year ended December 31, 2017. On May 8, 2017, the Company entered into a one-year consulting agreement for advisory services with a third-party investment relations firm. On May 18, 2017, the Company issued to the consultant 30,000 shares of the Company’s common stock valued at $219,000, which was fully recognized in the year ended December 31, 2017. The shares are considered to be a fully earned, nonrefundable, non-apportionable and non-ratable retainer as consideration for undertaking the agreement. In addition, the Company will pay the consultant $5,000 per month in cash for the term of the agreement. On May 25, 2017, the Company entered into a 20-month consulting agreement with a third-party advisory firm for consideration of 20,000 shares of the Company’s common stock. The stock was issued on May 25, 2017 and fair valued at $7.70 per share or $154,000, which will be amortized over the length of the agreement. During the year ending December 31, 2017, the Company recorded $56,138 in consulting expense related to this agreement. During the year ended December 31, 2018 an additional $92,299 in consulting expense was recorded. Potentially Dilutive Securities On January 1, 2017, the Company granted 25,000 options to an employee of the Company as compensation for being appointed the International Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $1.00 per share. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 25,000 options fully vested as of December 31, 2017. (See Note 16). On January 3, 2017, the Company granted 12,000 options to an employee of the Company as compensation for being appointed as a consultant of the Company. The options have an exercise period of five years with an exercise price of $2.00 per share. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 12,000 options fully vested as of December 31, 2017 (See Note 16). On January 1, 2018, the Company granted 25,000 options to an employee of the Company as compensation for being appointed the International Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $1.00 per share. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 25,000 options fully vested as of December 31, 2018 (See Note 16). Sales Pursuant to Regulation S On April 7, 2017, the Company issued shares of common stock and warrants pursuant to a private placement conducted under the exemptions from registration under Regulation S. Each unit sold to investors consists of $35,000 face value purchase price of 5,000 shares plus warrants to purchase the number of equivalent shares. The Company retains the right to accept less than the $35,000 face value from any investor at its discretion. The Company has entered into the following subscription agreements: On April 10, 2017, the Company sold 4,580 shares at $7.00 per share for a total purchase price of $32,060 to a private investor. The investor also received 4,580 warrants that were valued using the Black Scholes valuation model to have a fair value of $2,375 (See Note 16). On April 26, 2017, the Company sold 4,670 shares at $7.00 per share for a total purchase price of $32,690 to a private investor. The investor also received 4,670 warrants that were valued using the Black Scholes valuation model to have a fair value of $1,521 (See Note 16). On May 16, 2017, the Company sold 790 shares at $7.00 per share for a total purchase price of $5,530 to a private investor. The investor also received 790 warrants that were valued using the Black Scholes valuation model to have a fair value of $130 (See Note 16). On July 21, 2017, the Company sold 4,300 shares at $5.00 per share for a total purchase price of $21,500 to a private investor. The Company did not grant any warrants to the investor under this agreement. No options warrants or other potentially dilutive securities other than those disclosed above have been issued as of December 31, 2018. As of December 31, 2018 and 2017, the Company had 13,878,772 and 12,825,393 shares of Common Stock issued and 13,705,082 and 12,666,704 shares outstanding, respectively.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 9 - INCOME TAXES	The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended December 31, 2018 and 2017 is as follows: 12/31/2018 12/31/2017 US Income before income taxes $ (8,731,677 ) $ (6,209,768 ) Taxes under statutory US tax rates $ (1,833,652 ) $ (2,111,321 ) Increase (decrease) in taxes resulting from: Increase (decrease) in valuation allowance $ 554,452 $ 156,724 Foreign tax rate differential $ 164,394 $ 424,810 Tax Cuts and Jobs Act $ - $ 181,881 Permanent differences $ 1,628,906 $ 1,384,635 Purchase price adjustments $ 25,202 $ - Discrete items $ (318,892 ) $ - State taxes $ (146,148 ) $ (31,629 ) Income tax (expense) benefit $ 74,263 $ 5,100 On December 22, 2017, the Tax Cuts and Jobs Act (“The Act”), was signed into law by President Trump. The Act includes a number of provisions, including the lowering of the U.S. corporate tax rate from 35 percent to 21 percent, effective January 1, 2018 and the establishment of a territorial-style system for taxing foreign-source income of domestic multinational corporations. In December 2017, the SEC issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Act (“SAB118”), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment. The Company remeasured its deferred tax assets and liabilities as of December 31, 2017, applying the reduced corporate income tax rate and recorded a provisional decrease to the deferred tax assets of $181,881, with a corresponding adjustment to the valuation allowance. In the fourth quarter of 2018, we completed our analysis to determine the effect of the Tax Act and there were no material adjustments as of December 31, 2018. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities consist of the following: 12/31/2018 12/31/2017 Net Operating Loss Carryforward $ 904,877 $ 514,338 Nonqualified Stock Options 187,513 - Depreciation 1,602 - Total Deferred tax assets 1,093,992 514,338 Intangibles (10,729 ) - Goodwill (14,473 ) - Total Deferred tax liabilities (25,202 ) - Valuation allowance (1,068,790 ) (514,338 ) Net deferred tax assets (liabilities) $ - $ - At December 31, 2018, the Company had U.S. net operating loss carry forwards of approximately $2,422,876 that may be offset against future taxable income, subject to limitation under IRC Section 382. Of the $2.4 million, of Federal net operating loss carryforwards, $2.2 million begin to expire in 2031. The remaining balance of $.2 million is limited in annual usage of 80% of current year’s taxable income, but do not have an expiration. At December 31, 2018, the Company had Greece net operating loss carry forwards of approximately $847,896 that may be offset against future taxable income which begin to expire in 2019. At December 31, 2018, the Company had United Kingdom net operating loss carry forwards of approximately $847,896 that may be offset against future taxable income part or all of which may not be available to offset our future taxable income in the United Kingdom should there be a change in the nature or conduct of our business in the United Kingdom within the three years subsequent to the date of our acquisition of Decahedron. No tax benefit has been reported in the December 31, 2018 or 2017 consolidated financial statements due to the uncertainty surrounding the realizability of the benefit, based on a more likely than not criteria and in consideration of available positive and negative evidence. The Company applied the "more-likely-than-not" recognition threshold to all tax positions taken or expected to be taken in a tax return, which resulted in no unrecognized tax benefits as of December 31, 2018 and December 31, 2017, respectively.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 10 - RELATED PARTY TRANSACTIONS	On the date of our inception, we issued 2 million shares of our common stock to our three officers and directors which were recorded at no value (offsetting increases and decreases in Common Stock and Additional Paid-in Capital). Doc Pharma S.A. As of December 31, 2018, the Company has a prepaid balance of €1,867,239 ($2,139,109) and an accounts payable balance of €31,514 ($36,103), resulting in a net prepaid balance of €1,835,725 ($2,103,006) to Doc Pharma S.A., related to purchases of inventory. Additionally, the Company has a receivable balance of €38,323 ($43,903). As of December 31, 2017, the Company has a prepaid balance of €776,431 ($933,425) and an accounts payable balance of €133,756 ($160,801), resulting in a net prepaid balance of €642,675 ($772,623) to Doc Pharma S.A. related to purchases of inventory. During the years ended December 31, 2018 and 2017, the Company has purchased a total of €4,596,227 ($5,431,361) and €4,733,375 ($5,349,187) of products from Doc Pharma, respectively. During the years ended December 31, 2018 and 2017 the Company had €201,645 ($238,284) and €0 ($0) revenue from Doc Pharma, respectively. On November 1, 2015, the Company entered into a €12,000 ($12,662) Loan Agreement with Doc Pharma S.A, pursuant to which Doc Pharma S.A., paid existing bills of the Company in the amount of €12,000 ($12,662), excluding the Vendor Bills. The loan bears an interest rate of 2% per annum and was due and payable in full on October 31, 2016. As of December 31, 2018, the Company has an outstanding principal balance under this note of €12,000 ($13,474) and accrued interest expense of $836. Doc Pharma S.A is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the wife of Grigorios Siokas, the Company’s CEO and principal shareholder, who also served as a principal of Doc Pharma SA in the past. Medihelm S.A As of December 31, 2018, the Company has a prepaid balance of €2,459,805 ($2,817,953) and an accounts payable balance of £42,065 ($53,566), resulting in a net prepaid balance of $2,764,387 to Medihelm S.A. related to purchases of inventory. Additionally, the Company has a receivable balance of €127,292 ($145,826). During the years ended December 31, 2018 and 2017, SkyPharm purchased €9,564,899 ($11,302,842) and €9,027,639 ($10,202,135) of products from Medihelm, respectively, and Decahedron purchased £718,050 ($958,454) and £605,709 ($784,272) of products from Medihelm, respectively. During the years ended December 31, 2018 and 2017, SkyPharm had revenue of €1,055,435 ($1,247,208) and €1,265,184 ($1,429,784) from Medihelm, respectively. Medihelm S.A. is considered a related party to the Company due to the fact that the managing director of Medihelm is the mother of Nicholaos Lazarou, the managing director of the Company’s UK subsidiary, Decahedron. Grigorios Siokas On October 1, 2016, the Company borrowed €5,000 ($5,276) as a loan payable from Grigorios Siokas. The loan is non-interest bearing and had a maturity date of October 1, 2017. During the year ending December 31, 2017, the Company borrowed an additional €1,000 ($1,202). On September 30, 2018, the debt, amounting to €6,000 ($6,973) was transferred to the third-party purchaser of Amplerissimo pursuant to the Share Purchase Agreement. As of December 31, 2018, the Company had an outstanding principal balance of $0 and no accrued interest under this loan. During the year ended December 31, 2016, the Company borrowed €90,500 ($95,496) as additional loans payable from Grigorios Siokas. During the year ended December 31, 2017, the Company borrowed an additional €623,621 ($749,717) and, as of December 31, 2017, the Company paid back the entire outstanding balance of the loans or €714,121 ($858,516). During the year ended December 31, 2018, the Company borrowed €1,622,700 ($1,917,545) of loans payable from Grigorios Siokas and repaid €269,000 ($317,877) of these loans. These loans are non-interest bearing and have no maturity dates. As of December 31, 2018, the Company has an outstanding principal balance of the loans or €1,353,700 ($1,550,799). During the year ended December 31, 2018, the Company borrowed an additional $382,000 from Grigorios Siokas and repaid $155,000. These loans are non-interest bearing and have no maturity dates. As of December 31, 2018, the Company has an outstanding principal balance of $227,000 under these loans. On December 20, 2018, the €1,500,000 ($1,718,400) note payable, originally borrowed pursuant to a Loan Agreement with a third party lender, dated March 16, 2018, was transferred to Grigorios Siokas. The note bears an interest rate of 4.7% per annum and has a maturity date of March 18, 2019. As of December 31, 2018, the Company has an outstanding principal balance of €1,500,000 ($1,718,400) and accrued interest of €55,631 ($63,371). During the years ended December 31, 2018 and 2017, Grigorios Siokas was paid total compensation of $0 and $250,000, respectively. Grigorios Siokas is the Company’s CEO and principal shareholder, and is hence considered a related party to the Company. Ourania Matsouki During the year ended December 31, 2016, the Company borrowed €44,995 ($47,479) from Mrs. Matsouki, Grigorios Siokas’ wife and CEO of Doc Pharma. During the year ended December 31, 2017, the Company borrowed an additional €55,000 ($66,121). These loans have no formal agreement and bear no interest. As of December 31, 2017, the Company paid back the outstanding balance of €99,995 ($120,214) of these loans. During the year ended December 31, 2018, the Company borrowed an additional €30,000 ($34,368). As of December 31, 2018, the Company has paid back the outstanding balance of €30,000 ($34,368) of these loans. Dimitrios Goulielmos On November 21, 2014, SkyPharm entered into a Loan Agreement with Dimitrios Goulielmos, former Chief Executive Officer and a current director of the Company, pursuant to which the Company borrowed €330,000 ($401,115) from Dimitrios Goulielmos. The Loan bears an interest rate of 2% per annum and was due and payable in full on May 11, 2015. On November 4, 2015, €130,000 ($142,860) in principal and the related accrued interest of €733 ($806) was forgiven and the remaining balance of €200,000 will no longer accrue interest as part of the stock purchase agreement with Grigorios Siokas on November 4, 2015 referenced above. As of December 31, 2016, €60,000 ($63,312) of the loan was paid back. During the year ended December 31, 2017, an additional €70,500 ($84,755) was paid back. During the year ended December 31, 2018, the Company paid back an additional €16,000 ($18,907) and an outstanding principal balance of €53,500 ($61,290) and €0 ($0) accrued interest remains. Dimitrios Goulielmos is a current director and former CEO of the Company, and is hence considered a related party to the Company. Konstantinos Vassilopoulos During the year ended December 31, 2017, Konstantinos Vassilopoulos, the Company’s US Finance Manager, paid $10,179 of existing bills of the Company. There is no formal agreement related to these transactions. During the year ended December 31, 2018, the Company paid back $9,810. There is no formal agreement related to these transactions. As of December 31, 2018 and 2017 the outstanding balance under this loan was $369. During the year ended December 31, 2018, the Company borrowed and repaid an aggregate of $168,000 to Mr. Konstantinos Vassilopoulos. These loans have no formal agreement and bear no interest. As of December 31, 2018, an outstanding principal balance of $0 and $0 accrued interest remains. Nicholaos Lazarou In connection with the Decahedron SPA, on February 9, 2017, Decahedron, Medihelm S.A. and Nicholaos Lazarou entered into a liability transfer agreement whereby the loan provided from Decahedron to Nicholaos Lazarou prior to the acquisition would be cancelled in exchange for Nicholaos Lazarou’s personal assumption of approximately £172,310 ($233,118) owed to Medihelm S.A., a creditor of Decahedron. Following the acquisition of Decahedron, Nicholaos Lazarou is the managing director of the Company’s UK subsidiary, and is hence considered a related party to the Company. On December 19, 2017, the Company entered into a stock purchase agreement with an officer and director of the Company, whereby for consideration of €80,000 ($94,495) the Company purchased 20,000 shares of its common stock. As per the agreement, the sale and transfer of the shares occurred on December 19, 2017, the date of signing, however the Company is entitled to pay the full consideration in tranches until July 2018. As of December 31, 2017, the Company has paid consideration of €28,000 ($33,073) and had an amount due to related party of €52,000 ($61,422) recorded as accounts payable related party as of December 31, 2017. The shares were returned to the Company in February 2018. During the year ended December 31, 2018, the Company repaid the remaining balance of €52,000 ($61,448) and has an amount due to related party of €0 ($0) as of December 31, 2018. On June 18, 2018, the Company entered into a stock purchase agreement with an officer and director of the Company, whereby for consideration of €60,000 ($69,912) the Company repurchased 15,000 shares of its common stock. As per the agreement, the sale and transfer of the shares occurred on June 18, 2018, the date of signing, however the Company is entitled to pay the full consideration in tranches until November 2018. During the year ended December 31, 2018, the Company has paid consideration of €60,000 ($70,902) and has an amount due to related party of €0 ($0) as of December 31, 2018. On November 30, 2018, the Company entered into a stock purchase agreement with an officer and director of the Company, whereby for consideration of $60,000 the Company repurchased 20,000 shares of its common stock. As per the agreement, the sale and transfer of the shares occurred on November 30, 2018, the date of signing, however the Company is entitled to pay the full consideration in tranches until August 2019. During the year ended December 31, 2018, the Company has paid consideration of $11,317 and has an amount due to related party of $48,683 recorded as accounts payable related party as of December 31, 2018. Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.

LINES OF CREDIT

LINES OF CREDIT	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 11 - LINES OF CREDIT	The line of credit with National Bank of Greece is being renewed annually with a current interest rate of 6.00%. The maximum borrowing allowed was $1,374,720 at December 31, 2018. The outstanding balance was $766,575 at December 31, 2018. The line of credit with Alpha Bank of Greece is renewed annually with a current interest rate of 6.00%. The maximum borrowing allowed was $687,360 at December 31, 2018. The outstanding balance was $461,179 at December 31, 2018. The line of credit with Eurobank of Greece is being renewed annually with a current interest rate of 8.55%. The maximum borrowing allowed was $572,800 at December 31, 2018. The outstanding balance was $286,829 at December 31, 2018. Interest expense for the year ended December 31, 2018, was $32,275. Under the agreements, the Company is required to maintain certain financial ratios and covenants. These lines of credit were assumed in the Company’s acquisition of Cosmofarm. During the year ended December 31, 2018 the Company was in compliance with these ratios and covenants.

CONVERTIBLE DEBT

CONVERTIBLE DEBT	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 12 - CONVERTIBLE DEBT	November 15, 2017 Securities Purchase Agreement On November 15, 2017, the Company entered into a Securities Purchase Agreement with two institutional investors (the “Buyers”), pursuant to which the Company issued on November 16, 2017 for a purchase price of $3,000,000, $3,350,000 in aggregate principal amount of Senior Convertible Notes (the “Existing Notes”) to the Buyers, convertible into approximately 670,000 shares of the Company’s common stock, par value $.001 per share (the “Common Stock”) at $5.00 per Share and five-year warrants (the “Warrants”) to purchase an aggregate of 536,000 shares of Common Stock exercisable at $7.50 per share. The Notes contained an original issue discount of $350,000. Of the $3,000,000 purchase price, $240,000 went directly to financing costs (see below) and $74,000 went directly to legal fees such that the Company received net proceeds of $2,686,000. On February 20, 2018, the Company entered into two separate Amendment and Exchange Agreements (“Exchange Agreements”) with the Buyers for new senior convertible notes (“New Notes”) in exchange for existing notes. Each New Note is identical in all material respects to the Existing Note, except that (i) the New Note was not convertible into shares of the Company’s common stock (the “Common Stock”) until April 20, 2018; (ii) all future cash installment payments under such New Note will be made at a redemption price equal to 112% of the applicable installment amount; (iii) the Company’s existing obligation to initially deliver pre-delivery shares of its common stock to the holder of such New Note was deferred until April 20, 2018; and (iv) at any time on or before June 20, 2018, the Company had the right, at its option, to redeem all, or any part, of the amounts then outstanding under such New Note in cash at a redemption price equal to 125% of such amounts then outstanding under such New Note. The Company will repay the principal amount of the Notes in equal monthly installments beginning on January 1, 2018 and repeating on the first business day of each calendar month thereafter until the fourteenth (14th) month anniversary date of issue. On September 26, 2018, the Company entered into a second amendment which extended the maturity dates of the notes to February 1, 2019. No interest shall accrue under the Notes unless and until an Event of Default (as defined) has occurred and is not cured. As of December 31, 2018, no such event of default had occurred. On April 24, 2018, 670,001 per-delivery shares were issued. Eighty-five (85%) percent of any cash proceeds received by the holders of the Notes from the sale of pre-delivery shares issued as collateral shall be applied against the particular installment amount then due. The Notes are senior in right of payment to all existing and future indebtedness except Permitted Indebtedness which includes $12 million of senior secured indebtedness of the Company and its subsidiaries under the above described Synthesis loan agreements, plus a defined amount of purchase money indebtedness in connection with bona fide acquisitions. The Company evaluated the debt modification in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment as the 10% cash flow test was met. As a result, the Existing Notes were written off and the New Notes were recorded at fair value as of February 20, 2018. The Company wrote off the remaining principal balance of $2,871,429 of the Existing Notes along with the remaining $2,596,838 of debt discounts related to the Existing Notes of which $1,140,711 was a reduction to additional paid-in-capital representing the intrinsic value of the existing beneficial conversion feature. The Company recorded the New Notes in the amount of $3,216,000 and a total debt discount of $3,216,000 in relation to the intrinsic value of the new beneficial conversion feature of $2,880,000 and an original issue discount of $336,000. This resulted in a net loss on extinguishment of debt in the amount of $1,464,698 and additional net equity related to the beneficial conversion feature of $1,739,289. The Notes were not convertible until April 18, 2018 pursuant to the February 20, 2018 amendment. Beginning April 20, 2018, the Holder may convert the Notes into shares of Common Stock at the rate of $5.00 per share. In the event of an issuance of Common Stock for a consideration less than the Conversion Price (other than Excluded Securities, as defined) the Conversion Price shall be reduced to the price of the dilutive issuance, (the “Conversion Price”). Upon an Event of Default (as defined), the Buyers may convert at an alternative conversion price equal to the lower of the then applicable Conversion Price or seventy-five (75%) percent of the Volume-Weighted Average Price (as defined, the “VWAP”). The Company valued the beneficial conversion feature of the Existing Notes at intrinsic value and recorded $1,140,711 to debt discount, of which $405,743 was amortized through February 19, 2018. On February 20, 2018, the remaining debt discount was written off and the Company recorded a new debt discount as discussed above. The Notes are senior in right of payment to all existing and future indebtedness of the Company except Permitted Indebtedness (as defined in the Note), including $12 million of senior secured indebtedness of the Company and its subsidiaries under an existing senior loan agreement, plus defined amounts of purchase money indebtedness in connection with bona fide acquisitions. The Notes include customary Events of Default and provide that the Buyers may require the Company to redeem (regardless of whether the Event of Default has been cured) all or a portion of the Notes at a redemption premium of one hundred twenty-five (125%) percent, multiplied by the greater of the conversion rate and the then current market price. The Buyers may also require redemption of the Notes upon a Change of Control (as defined) at a premium of one hundred twenty-five (125%) percent. On December 12, 2018, the Company entered into a Third Amendment and Exchange Agreement (“Third Exchange Agreement”) with the Buyers whereby the existing 536,000 warrants issued to such investors in connection with the November 15, 2017 Securities Purchase Agreement were retired in exchange for 727,683 new warrants. Additionally, the investors agreed to convert $1,333,333 of the debt related to the September 4, 2018 Securities Purchase Agreement at a reduced conversion price of $3.478. The Company issued those 383,363 shares on December 13, 2018. The Third Exchange agreement was considered to be an inducement to conversion and accounted for in accordance with ASC 470-20. Accordingly, the Company recorded a modification expense of $1,778,952 for the year ended December 31, 2018. The modification expense was based on the change in the fair value of the warrants and conversion feature before and after the modification using the Black-Scholes option-pricing model on the date of the modification using the following assumptions: pre-modification: post-modification The Warrants had a five-year term and were exercisable into 536,000 shares of Common Stock beginning May 16, 2018, which was six months after the issue date. The Warrants were exercisable at $7.50 per share subject to full ratchet anti-dilution protection (see above). As of December 31, 2018, there were no anti-dilution trigger events. The Warrants would have been exercisable on a cashless basis if a registration statement was not effective covering the resale of the underlying Warrant Shares. The Company calculated the warrants at relative fair value of $1,545,288, which was recognized as a discount to the Existing Notes of which $347,418 was amortized as interest expense through February 19, 2018. On February 20, 2018, the remaining balance was reversed due to the Exchange Agreement as discussed above. On December 12, 2018, pursuant to the Third Amendment and Exchange Agreement, the 536,000 warrants were retired in exchange for the issuance of 727,683 new warrants that are exercisable at $6.00 per share and have the same rights and privileges as the original warrants and expire on December 11, 2023. Conversion of the Notes and exercise of the Warrants are each subject to a blocker provision which prevents any holder from converting or exercising, as applicable, the Notes or the Warrants, into shares of Common Stock if its beneficial ownership of the Common Stock would exceed 4.99% (subject to adjustment not to exceed 9.99%) of the Company’s issued and outstanding Common Stock (each, a “Blocker”). The Company filed, within thirty (30) days of the Closing, a registration statement covering one hundred fifty (150%) percent of the maximum number of shares, underlying the Notes and Warrants pursuant to a registration rights agreement with the Buyers (the “Registration Rights Agreement”). The Post-Effective Amendment to the registration statement (No. 333-222061) was declared effective on May 14, 2018. As a condition to the closing of the Financing, each Buyer, severally, was required to execute a leak-out agreement (each, a “Leak-Out Agreement”) restricting such Buyer’s sale of shares of Common Stock underlying the Notes and Warrants on any Trading Day to not more than such Buyer’s pro rata allocation of the greater of (x) sales with net proceeds of an aggregate of $20,000 or (y) twenty-five (25%) percent of the daily average trading volume of the Company’s Common Stock. If after the closing of the Financing there is no Event of Default under the Notes, the VWAP of the Company’s Common Stock for three (3) trading days is less than $1.50 per share, the Company may further restrict the Buyers from selling at less than $1.50 per share; provided that the portion of the Notes subject to redemption on each Installment Date shall thereafter double. On November 15, 2017, in connection with the $3,350,000 Securities Purchase Agreement, Roth Capital Partners, LLC (“Roth”), as the Company’s exclusive placement agent, received a cash commission for the transaction equal to eight (8%) percent of the total gross proceeds of the offering, or $240,000 and the issuance of five-year warrants to purchase eight (8%) percent of the shares of common stock issued or issuable in this offering (excluding shares of common stock issuable upon exercise of any warrants issued to investors), or 53,600 shares; and, will receive eight (8%) percent of any cash proceeds received from the exercise of any warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The warrants are exercisable six months after the issue date or May 16, 2018 and were valued at a fair value of $386,003 which was fully expensed during the year ended December 31, 2017. The $240,000 cash commission was recorded as debt discount and will be amortized over the term of the Notes. During the year ended December 31, 2018, there were principal conversions in the amount of $386,062 and the Company repaid principal in the amount of $2,919,286, such that the remaining outstanding principal balance of the Notes as of December 31, 2018 is $149,938. The Company recorded a total of $3,350,000 of debt discounts related to the above Existing Notes in the year ended December 31, 2017. A total of $360,890 was amortized during the year ended December 31, 2017 and an additional $392,272 related to the debt discount of the Existing Notes was amortized through February 19, 2018. As a result of the Exchange Agreement discussed above, the debt discounts of the Existing Notes were written off and a total of $3,169,672 of debt discounts were recorded during the year ended December 31, 2018. The debt discounts are being amortized over the term of the debt. Amortization of the debt discounts of the New Notes for the year ended December 31, 2018 was $3,124,058. September 4, 2018 Securities Purchase Agreement On September 4, 2018, the Company entered into a Securities Purchase Agreement with two institutional investors (the “Buyers”) pursuant to which the Company issued for a purchase price of $2,000,000, $2,233,333 in aggregate principal amount of Senior Convertible Notes (the “September 2018 Notes”) to the Buyers, convertible into 372,223 shares of the Company’s common stock, par value $.001 per share at $6.00 per share (with the exception of the conversion related to the Third Exchange Agreement), and warrants to purchase an aggregate of 357,334 shares of Common Stock exercisable at $7.50 per share (the “Warrants”). The Notes contained an original issue discount of $233,332. Of the $2,000,000 purchase price, $140,000 went directly to financing costs (see below) and $15,000 went directly to legal fees such that the Company received net proceeds of $1,845,000. The September 2018 Notes provide that the Company will repay the principal amount of Notes in equal monthly installments including a 5% installment fee, which is recorded as interest expense, beginning on November 1, 2018 and repeating on the first business day of each calendar month thereafter until May 1, 2019. During the year ended December 31, 2018, the Company has recorded $31,905 in installment fees. No annual interest will accrue under the Notes unless and until an Event of Default has occurred and is not cured and will then accrue interest at 18% per annum. The Notes are convertible at any time by the Holder into shares of Common Stock at the rate of $6.00 per share (with the exception of the conversion pursuant to the Third Exchange Agreement), subject to full ratchet anti-dilution adjustment (the “Conversion Price”). According to the original terms of the agreement, the Company was to pre-deliver up to 372,222 shares of common stock to the Buyers. Eighty-five percent (85%) of any cash proceeds received by the Buyers from the sale of the Pre-Delivery Shares would then be applied against the particular installment amount due on such Installment Date under the Note. The Company had three months to deliver the Pre-Delivery shares, however the debt was repaid prior to the opportunity to deliver those shares. The Registration Statement (No. 333-22781 covering 150% of the number of shares underlying the Notes and warrants was declared effective on November 1, 2018. Upon an Event of Default (regardless of whether such event has been cured), the Buyers may convert at an alternative conversion price equal to the lower of the then applicable Conversion Price or seventy-five (75%) percent of the then Volume-Weighted Average Price (as defined, the “VWAP”). The Company valued the beneficial conversion feature of the Existing Notes at intrinsic value and recorded $934,922 to debt discount, which will be amortized over the life of the Notes. The Notes are pari passu in right of payment to the November Notes and senior in right of payment to all other existing and future indebtedness of the Company except Permitted Indebtedness (as defined in the Note), including $12 million of senior secured indebtedness of the Company and its subsidiaries under an existing senior loan agreement, plus defined amounts of purchase money indebtedness in connection with bona fide acquisitions. The Notes include customary Events of Default and provide that the Buyers may require the Company to redeem (regardless of whether the Event of Default has been cured) all or a portion of the Notes at a redemption premium of one hundred twenty-five (125%) percent, multiplied by the greater of the conversion rate and the then current market price. The Buyers may also require redemption of the Notes upon a Change of Control (as defined) at a premium of one hundred twenty-five (125%) percent. The Company has the right to redeem the Notes at any time, in whole or in part, in cash at a price equal to 120% of the then outstanding conversion amount. The Warrants are exercisable into 357,334 shares of Common Stock equal to eighty (80%) percent of the number of shares of common stock the Buyers would receive if the Notes were fully converted (at an assumed price of $5.00 per share) upon the date of issuance of the Notes. The Warrants are exercisable at $7.50 per share for a five-year term commencing March 1, 2019 subject to full ratchet anti-dilution protection. The Warrants will be exercisable on a cashless basis if a registration statement is not effective covering the resale of the underlying Warrant Shares. The Company calculated the warrants at relative fair value of $910,078, which was recognized as a discount to the Notes and is being amortized as interest expense over the remaining term of the Notes. Conversion of the Notes and exercise of the Warrants are each subject to a blocker provision which prevents any holder from converting or exercising, as applicable, the Notes or the Warrants, into shares of common stock if its beneficial ownership of the common stock would exceed 9.99% of the Company’s issued and outstanding common stock (a “Blocker”). As a condition to the closing of the Financing, each Buyer executed a leak-out agreement which replaced the leak-out agreements entered into in November 2017 (each, a “Leak-Out Agreement”) restricting such Buyer’s sale of shares of common stock underlying the Notes and Warrants on any trading day to not more than such Buyer’s pro rata allocation of the greater of (x) sales with net proceeds of an aggregate of $20,000 or (y) twenty-five (25%) percent of the daily average trading volume of the Company’s Common Stock. If after the closing of the Financing the VWAP of the Company’s common stock for three (3) trading days is less than $1.50 per share, the Company may further restrict the Buyers from selling at less than $1.50 per share; provided that the portion of the Notes subject to redemption on each Installment Date shall thereafter double. Roth Capital Partners, LLC (“Roth”), as the Company’s exclusive placement agent, received a cash commission for this transaction equal to seven (7%) percent of the total gross proceeds of the offering, or $140,000, and the issuance of five-year warrants to purchase seven (7%) percent of the shares of common stock issued or issuable in this offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors), or 26,056 shares; and will receive seven (7%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The warrants are exercisable six months after the issue date or March 4, 2019, at $6.00 per share and were valued at a fair value of $157,969 which was fully expensed during the nine months ended September 30, 2018. The $140,000 cash commission was recorded as debt discount and will be amortized over the term of the Notes. During the year ended December 31, 2018 there were principal conversions in the amount of $1,333,333 at a conversion price of $3.478 pursuant to the Third Exchange Agreement and the Company repaid principal of $638,095, such that the remaining outstanding principal balance of the Notes as of December 31, 2018 was $261,903. The Company recorded a total of $2,233,332 of debt discounts related to the above Notes during the year ended December 31, 2018. The debt discounts are being amortized over the term of the debt. Amortization of the debt discounts for the year ended December 31, 2018 was $2,049,232.

DEBT

DEBT	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 13 - DEBT	On March 4, 2015, the Company entered into a $9,000 Loan Agreement with Mr. Angelo Drakopoulos, pursuant to which Mr. Drakopoulos paid a $9,000 outstanding bill on behalf of the Company. The loan bears an interest rate of 8% per annum and was due and payable in full on May 5, 2016. As of December 31, 2017, the Company has repaid the principal balance under this note of $9,000 and the related accrued interest expense of $1,463 in full. On November 5, 2015, the Company entered into a Loan Agreement pursuant to which the Company borrowed €20,000 ($21,812), of which proceeds of €10,000 ($10,906) have been received as of December 31, 2016. The loan bears an interest rate of 1% per annum and was due and payable in full on November 5, 2016. The Company repaid €2,000 ($2,110) as of December 31, 2016. During the year ended December 31, 2017, the Company repaid the outstanding balance of €8,000 ($9,618) and accrued interest of €115 ($138) in full and reversed the €10,000 ($12,022) receivable that was never received. On November 5, 2015, the Company entered into a Loan Agreement pursuant to which the Company borrowed €80,000 ($87,248) of which proceeds of €70,000 ($76,342) have been received as of December 31, 2016. The loan bears an interest rate of 5% per annum and was due and payable in full on November 5, 2016. As of December 31, 2016, the outstanding balance was €65,000 ($68,588). During the year ended December 31, 2017, the Company repaid €55,000 ($66,121) of principal and €3,400 ($4,087) in accrued interest in full and also reversed the €10,000 ($12,022) receivable that was never received. On November 16, 2015, the Company entered into a Loan Agreement with Panagiotis Drakopoulos, former Director and former Chief Executive Officer, pursuant to which the Company borrowed €40,000 ($42,832) as a note payable from Mr. Drakopoulos. The note bears an interest rate of 6% per annum and was due and payable in full on November 15, 2016. During the year ended December 31, 2017, the Company repaid €17,000 ($20,437) of principal and €2,060 ($2,477) of accrued interest in full. During the year ended December 31, 2018, the Company paid back an additional €10,000 ($11,456). As of December 31, 2018, the Company has an outstanding principal balance of €13,000 ($14,893) and accrued interest of €3,088 ($3,538). During the year ended December 31, 2015, the Company borrowed €30,000 ($32,577) as a loan payable from Mr. Panagiotis Drakopoulos, former Director and former Chief Executive Officer. The loan had no formal agreement and bore no interest. During the year ended December 31, 2016, the Company repaid €13,000 ($13,718) of the loan. During the year ended December 31, 2017 the Company repaid the remaining €17,000 ($20,437) in full. On February 5, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €20,000 ($22,262). The loan bore an interest rate of 6% and had no maturity date. During the year ended December 31, 2017, the Company repaid the €20,000 ($24,044) loan and accrued interest of €1,020 ($1,226) in full. On March 4, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €50,000 ($55,050) from a third party. On May 04, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed an additional €50,000 ($57,430). The loans bore an interest rate of 6% and a maturity date of March 4, 2017 and May 4, 2017, respectively. During the year ended December 31, 2017, the Company repaid both loans in the amount of €100,000 ($120,220) and accrued interest of €1,175 ($1,413) in full. On April 19, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €100,000 ($113,750). The loan bore an interest rate of 6% and matured on April 19, 2017. During the year ended December 31, 2017, the Company repaid the loan in the amount of €100,000 ($120,220) and accrued interest of €3,100 ($3,727) in full. On April 22, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €38,000 ($42,708). The loan bore an interest rate of 6% and matured on April 22, 2017. During the year ended December 31, 2017, the Company repaid the loan in the amount of €38,000 ($45,684) and accrued interest of €1,777 ($2,136) in full. On May 24, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €50,000 ($55,725). The loan bore an interest rate of 6% and matured on May 24, 2017. During the year ended December 31, 2017, the Company repaid the principal balance of €50,000 ($60,110) and accrued interest of €1,275 ($1,533) in full. On October 18, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €10,000 ($10,997). The loan bore an interest rate of 10% and matured on October 18, 2017. During the year ended December 31, 2017, the Company repaid the principal balance of €10,000 ($12,022) and accrued interest of €545 ($655) in full. On January 18, 2018, the Company entered into a Loan Agreement with a third party, pursuant to which the Company borrowed €75,000 ($91,785). The note bore an interest rate of 6.5% per annum and had a maturity date of January 17, 2019. The note was secured by a personal guaranty of Grigorios Siokas. During the year ended December 31, 2018, the Company repaid the loan and the related accrued interest of €1,748 ($2,002) in full. On March 16, 2018, the Company entered into a Loan Agreement with a third party, pursuant to which the Company borrowed €1,500,000 ($1,718,400) as a note payable. The note bears an interest rate of 4.7% per annum and has a maturity date of March 18, 2019. On December 20, 2018, the €1,500,000 ($1,718,400) note payable was transferred to Grigorios Siokas. As of December 31, 2018, the Company has an outstanding principal balance of €1,500,000 ($1,718,400) and accrued interest of €55,631 ($63,371). On April 2, 2018, the Company entered into a Loan Agreement with a third party, pursuant to which the Company borrowed €5,000 ($6,144) as a note payable. The note bears an interest rate of 4.7% per annum and has a maturity date of June 15, 2019. As of December 31, 2018, the Company repaid the loan in full. Due to the early repayment by the Company, an agreement was reached between the Company and the lender for no interest to accrue under this loan. Loan Facility Agreement On August 4, 2016, the Company’s wholly owned subsidiary SkyPharm entered into a Loan Facility Agreement, guaranteed by Grigorios Siokas, with Synthesis Peer-To Peer-Income Fund (the “Loan Facility” the “Lender”). The Loan Facility initially provided SkyPharm with a credit facility of up to $1,292,769 (€1,225,141). Any advance under the Loan Facility accrues interest at a rate of 10% per annum and requires quarterly interest payments commencing on September 30, 2016. The amounts owed under the Loan Facility shall be repayable upon the earlier of (i) three months following the demand of the Lender; or (ii) August 31, 2018. No prepayment is permitted pursuant to the terms of the Loan Facility. The Synthesis Facility Agreement as amended is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas. On September 13, 2016, SkyPharm entered into a First Deed of Amendment with the Loan Facility increasing the maximum loan amount to $1,533,020 as a result of the Lender having advanced $240,251 (€227,629) to SkyPharm. On March 23, 2017, SkyPharm entered into an Amended and Restated Loan Facility Agreement (the “A&R Loan Facility”), with the Loan Facility which increased the loan amount to an aggregate total of $2,664,960 (€2,216,736) as a result of the lender having advanced $174,000 (€164,898) in September 2016, $100,000 (€94,769) in October 2016, $250,000 (€236,922) in November 2016, $452,471 (€428,800) in December 2016, $155,516 (€129,360) in January 2017, $382,327 (€318,023) in July 2017 and $70,000 (€58,227) in December 2017. The A&R Loan Facility amends and restates certain provisions of the Loan Facility Agreement, dated as of August 4, 2016, by and among the same parties. Advances under the A&R Loan Facility continue to accrue interest at a rate of 10% per annum from the applicable date of each drawdown and require quarterly interest payments. The A&R Facility now permits prepayments at any time. The amounts owed under the A&R Loan Facility shall be repayable upon the earlier of (i) seventy-five days following the demand of the Lender; or (ii) August 31, 2018. The A&R Loan Facility is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas (the “Pledged Shares”). The A&R Loan Facility was also amended to provide additional affirmative and negative covenants of Sky Pharm and the Guarantor during the term of loans remain outstanding, including, but not limited to, the consent of the Lender in connection with (i) the Company or any of its subsidiaries incurring any additional indebtedness; or (ii) in the event of any increase in the Company’s issued and outstanding shares of Common Stock, the Pledged Shares shall be increased to an amount equal to a minimum of ten percent (10%) of the issued and outstanding shares of the Company. On April 18, 2018, the Company entered into an amendment with the Lender that was effective as of January 1, 2018, pursuant to which the maturity dates for all advances was extended to December 31, 2021. Additionally, the interest rate was amended such that the interest rate for all advances is 4% plus the 3-Month Libor rate. The Loan Facility also forgave €35,060 ($40,000) in fees related to the July 6, 2017 advance. As a result, the Company reduced the unamortized portion of debt discount that related to those fees and recorded a gain on debt settlement of €19,763 ($23,354). As of December 31, 2018, the outstanding balance under this note was $3,078,442 (€2,687,187) and accrued interest expense of $414,830 (€362,107) has been recorded. The Company recorded a total of €155,060 ($191,034) in debt discounts related to this note in prior years. The debt discounts are being amortized over the term of the debt. As a result of the April 18, 2018 amendment, the Company reduced the unamortized debt discount by €20,237 ($20,237). The Company amortized a total of €92,661 ($114,158) in prior years. Amortization of the debt discounts for the year ended December 31, 2018 was €42,162 ($56,043). Bridge Loans On March 16, 2017 and March 20, 2017, SkyPharm entered into loan agreements with the Synthesis Peer-To Peer-Income Fund (the “Bridge Loans”). The Bridge Loans provided to SkyPharm loans of €41,590 ($50,000) and €100,000 ($120,220), respectively, during the year ended December 31, 2017. The Bridge Loans accrue interest at a rate of 10% per annum and were repayable on April 16, 2017 and April 20, 2017, respectively, together with all other amounts then accrued and unpaid. On April 16, 2017, the maturity dates were amended for no additional consideration or change in terms and conditions. The maturity dates of both loans were amended, and they matured on May 16, 2017 and May 20, 2017, respectively. Pursuant to the April 18, 2018 agreement and effective January 1, 2018, the Company reached an agreement with Synthesis Peer-To-Peer Income Fund such that the March 20, 2017 loan would have a fixed USD payoff amount of $106,542. As a result of this agreement the Company recorded a gain on settlement of debt of €16,667 ($19,695) related to the reduction of the USD payoff amount and an additional gain on settlement of debt of €3,950 ($4,668) related to interest that had accrued on the original amount of the loan. The Company has accrued interest expense of an aggregate total of €14,715 ($16,857) for both loans and the outstanding balances of these loans was €43,645 ($50,000) and €93,001 ($106,542), respectively, as of December 31, 2018. On May 5, 2017, SkyPharm entered into a loan agreement with Synthesis Peer-To-Peer Income Fund for €31,388 ($34,745). The loan accrues interest at a rate of 10% per annum and matured on September 30, 2017. The Company has accrued interest expense of €3,410 ($3,906) and the outstanding balance on this loan was €30,329 ($34,745) as of December 31, 2018. On April 18, 2018, the Company entered into an amendment pursuant to which the maturity dates for all of the above Bridge Loan advances were extended to December 31, 2021 for no additional consideration. Additionally, the interest rate was amended such that, effective January 1, 2018, the interest rate for all advances is 4% plus the 3-Month Libor rate. Trade Facility Agreements On April 10, 2017, Decahedron entered into a Trade Finance Facility Agreement (the “Decahedron Facility”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”). The Decahedron Facility provides the following material terms: • The Lender will provide Decahedron a facility of up to €2,750,000 ($3,150,400) secured against Decahedron’s receivables from the sale of branded and generic pharmaceutical sales. • The total facility will be calculated as 95% of the agreed upon value of Decahedron’s receivables. • The term of the Decahedron Facility will be for 12 months. • The obligations of Decahedron are guaranteed by the Company pursuant to a Cross Guarantee and Indemnity Agreement. • The Lender has the right to make payments directly to Decahedron’s suppliers. • The following fees should be paid in connection with the Decahedron Facility: o 2% of the maximum principal amount as an origination fee. o A one percent (1%) monthly fee. The current draw on the Decahedron Facility is $0. On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the “SkyPharm Facility”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”). The SkyPharm Facility provides the following material terms: • The Lender will provide SkyPharm a facility of up to €2,000,000 ($2,291,200) secured against SkyPharm’s receivables from the sale of branded and generic pharmaceutical sales. In the event that accounts receivable becomes uncollectible, the Company will be obligated to pay back the notes in full. • The total facility will be calculated as 95% of the agreed upon value of Decahedron’s receivables. • The term of the SkyPharm Facility will be for 12 months. • The obligations of SkyPharm are guaranteed by the Company pursuant to a Cross Guarantee and Indemnity Agreement. • The Lender has the right to make payments directly to SkyPharm’s suppliers. • The following fees should be paid in connection with the SkyPharm Facility: o 2% of the maximum principal amount as an origination fee. o A one percent (1%) monthly fee. The Company obtained consents from Synthesis Peer-to-Peer Income Fund in connection with obtaining the Lender. On November 16, 2017, SkyPharm signed an amended agreement with Synthesis Structured Commodity Trade Finance Limited that increased the maximum aggregate facility limit from €2,000,000 ($2,291,200) to €6,000,000 ($6,873,600). All other terms of the original agreement remain the same. The Company also obtained consents from Synthesis Peer-to-Peer Income Fund in connection with obtaining the November 2017 convertible debt financing. On May 12, 2018, the Company borrowed an additional €270,000 ($247,117) in funds. On May 16, 2018, SkyPharm S.A., as Commodity Buyer, entered into a Supplemental Deed of Amendment (the “Deed”) relating to a Trade Finance Facility dated May 12, 2017, as amended, with Synthesis Structured Commodity Trade Finance Limited (“Synthesis”), as Loan Receivables Originator. Under the Trade Finance Facility (the “TFF”) first entered into on May 12, 2017, as amended, there was a principal balance of €5,866,910 ($5,369,678) outstanding as of March 31, 2018. SkyPharm made a payment of €1,000,000 ($1,123,600) of interest and principal on May 31, 2018 under the terms and conditions of the Deed. Additionally, the maturity date for the facility has been amended such that, the full principal amount is to be repaid no later than May 31, 2021, subject to a repayment schedule to be agreed upon by SkyPharm and Synthesis Structure Commodity Trade Finance Limited. Synthesis Structure Commodity Trade Finance Limited may extend this final repayment date at its sole discretion. The TFF was amended to provide, among other things: • A listing of approved purchasers; • To permit SkyPharm to request Synthesis to make payments under the TFF directly to SkyPharm so that SkyPharm can discharge its obligations to a commodity seller directly; • To prohibit SkyPharm from entering into a commodity contract which grants more than seventy-five (75) days delay between the payment for products and receipt of the purchase price and placed other limitations on terms of commodity contracts; • If Grigorios Siokas, CEO of Cosmos Holdings Inc. (“Cosmos”), ceases to own or control at least fifty-one (51%) percent of the shares of Cosmos, or SkyPharm ceases to be a wholly-owned subsidiary of Cosmos, either event shall constitute an Event of Default (as defined); • The maximum aggregate amount of the TFF is €15,000,000, although there is no commitment for any future loans under the TFF; • The interest rate on the TFF for: (i) all lending in U.S. dollars is the one-month LIBOR plus six (6%) percent margin; and (ii) for all lending in Euro, the one-month Euribor Rate plus six (6%) percent per annum, commencing June 1, 2018. • Synthesis is permitted to terminate the TFF at any time and demand repayment of all outstanding principal and interest in full within six (6) months from the date of notification. The Deed is conditioned upon, among other things, execution and perfection of a Bulgarian Amended Pledge (“BAP”) having priority over the Bulgarian Pledge Accounts with Unicredit Bulbank AD; and the Approved Purchasers are to make all payments to SkyPharm directly to the BAP. On May 16, 2018, SkyPharm and Synthesis also entered into an Account Merge Agreement (the “Pledge”) as a requirement under the above-described Deed. Under the Pledge, Synthesis is to receive a first ranking securities interest in SkyPharm’s outstanding receivables under the Bulgarian bank account. On October 17, 2018, the Company entered into a further amended agreement with Synthesis whereby the current balance on the TFF as of October 1, 2018, which was €4,866,910 ($5,629,555) and related accrued interest of €453,094 ($524,094) would be split into two principal balances of Euro €2,000,000 and USD $4,000,000. Interest on the new balances commenced on October 1, 2018 at 6% per annum plus one-month Euribor, when it is positive, on the Euro balance and 6% per annum plus one month Libor on the USD balance. The Company will replay the principal amounts of each balance beginning no later than August 31, 2018 in quarterly installments of €125,000 and US $150,000. The loan matures on August 31, 2021. The Company evaluated the amended agreement under ASC 470-50 and concluded that it did not meet the 10% cash flow test and recorded debt modification expense of $138,110. As of December 31, 2018, the Company has principal balances of €2,000,000 ($2,291,200) and $4,000,000 under the TFF and the Company has accrued $0 and $19,834, respectively in interest expense related to this agreement. The Company recorded a total debt discount of €117,338 ($137,063) in origination fees associated with these loans, which was amortized over the original terms of the agreements. Amortization of debt discount for year ended December 31, 2017 was €61,295 ($69,269). Amortization of the debt discount for the year ended December 31, 2018 was €56,043 ($66,226) and resulted in the full amortization of the debt discount. Distribution and Equity Agreement As discussed in Note 5 above, the Company entered into a Distribution and Equity Acquisition Agreement with Marathon. The Company was appointed the exclusive distributor of the Products initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. As consideration for its services, Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in Common Shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. As discussed in Note 5, the Company attributed no value to the shares received in Marathon pursuant to (a) above. In relation to the CAD $ 2 million cash received noted in (b) the prior paragraph, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $ 2 million). If settlement were to occur on December 31, 2018, the Company would be required to issue 337,158 Common Shares to settle its debt obligation. The Company could be obligated to potentially issue an unlimited number of common shares to settle its Share-settled debt obligation. If such events were to occur, the Company would be required to increase its authorized share capital and since increasing the authorized share capital is within the control of the Company, as our CEO controls greater than 50% of the outstanding common stock of the Company, the original classification of equity-classified financial instruments issued by the Company were not affected. None of the above loans were made by any related parties.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 14 - COMMITMENTS AND CONTINGENCIES	Legal Matters From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. As of December 31, 2018, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s operations. Operating Leases The Company conducts its operations from an office located in Chicago, Illinois for which beginning in January 2015, the monthly rent expense was $709, which has been paid through December 31, 2017. The lease expired as of May 31, 2017, however, the Company has negotiated and entered into a two-year amendment to that lease that commenced as of June 1, 2017 through May 31, 2019. The monthly rate from June 1, 2017 through May 31, 2018 was $709 per month and increased to $730 per month from June 1, 2018 through May 31, 2019. Rent expense for the years ended December 31, 2018 and 2017, was $8,651 and $8,502, respectively. Prior to the sale on September 30, 2018, the offices of Amplerissimo were located at 9, Vasili, Michaelidi Street, 3026, Limassol, Cyprus. The Company had a one-year lease which commenced on July 29, 2013 and was last renewed through July 2018, at the rate of €110 per month. Rent expense for the years ended December 31, 2018 and 2017 was $1,183 and $1,492, respectively. The offices of SkyPharm are located at 5, Agiou Georgiou Street 57001, Pylaia, Thessaloniki, Greece. The Company has a six-year lease that commenced on September 1, 2014 at the rate of €4,325 ($4,955) per month. In December 2015, the lease was revised to include an additional rental of the first floor at a rate of €800 ($916) per month. The lease was further revised in March 2016 to include another additional rental of the first floor at a rate of €800 ($916) per month beginning in May 2016. On May 30, 2016, the lease was revised again to include an additional rental of space at a rate of €1,825 ($2,091) per month beginning in June 2016. On March 23, 2017, SkyPharm entered into an additional three-year lease at a rate of €1,250 ($1,432) per month that commenced May 2017. As a result, the total monthly lease amount is now €9,000 ($10,310) per month. Rent expense for the years ended December 31, 2018 and 2017 was €108,000 ($127,624) and €103,000 ($116,400) respectively. The offices of Decahedron are located at Unit 11, Spire Greene Centre, Harlow, CM19 5TR, Essex, U.K., for which we pay approximately ₤1,908 ($2,430) per month, under an amendment to a lease dated October 25, 2011, which commenced on October 25, 2016 and expires on October 24, 2021. Rent expense for the year ended December 31, 2018 and from the date of acquisition through December 31, 2017 was ₤29,789 ($39,762) and ₤20,992 ($27,180), respectively. As of December 31, 2018, the offices of Cosmofarm were located at Herakleous 39, Neos Kosmos, Athens, Attiki, Greece, 11743. The lease expired of €1,400 ($1,654) per month expired on March 31, 2019. Cosmofarm has subsequently moved its principal offices to Gonata Stylianou 15, Peristeri, Attiki, Greece 12133. The Company has a ten-year lease which commenced on July 18, 2018, at the rate of €3,333 ($3,809), subject to a grace period until September 30, 2018. Rent expense did not accrue from July 18, 2018, to September 30, 2018. The Company rents additional square footage at Missonos 15-17, Neos Kosmos, Athens, Attiki, Greece, 11743. The Company has a three-year lease which commenced on May 1, 2017, at a rate of €400 ($457) per month. Future minimum operating lease commitments consisted of the following at December 31, 2018: Year Ended December 31, Amount (USD) 2019 $ 207,853 2020 $ 118,054 2021 $ 70,121 2022 $ 45,824 2023 $ 45,824 Thereafter $ 164,203 $ 651,879 Capital Leases The Company leases mechanical equipment under capital leases. The following is a schedule of future minimum lease payments, together with the present value of minimum lease payments under capital leases, at December 31, 2018: Year Ending December 31, Amount (USD) 2019 36,801 2020 14,955 Less amount representing interest (2,217 ) Present value of minimum lease payments 49,539 Less current portion (34,805 ) 14,734 Interest expense for the years ended December 31, 2018 and 2017 was $256 and $0, respectively. Intellectual Property Sale Agreement On October 1, 2016, the Company entered into an Intellectual Property Sale Agreement with Anastasios Tsekas and Olga Parthenea Georgatsou (the “IPSA”) for the purchase of certain intellectual property rights relating to proprietary pharmaceutical formulas and any related technical information arising or related thereto (the “Intellectual Property”). The IPSA provides that the sellers shall be entitled to an aggregate of 200,000 shares of common stock of the Company, none of which have been issued to date, and issuable as follows in equal parts to each seller: • 50,000 shares upon the successful conclusion of Preclinical Trials. • 50,000 shares upon the conclusion of Phase I testing. • 50,000 shares upon the conclusion of Phase II testing. • 50,000 shares upon the conclusion of Phase III testing. The Company has agreed to pay Anastasios Tsekas €1,500 per month until the first issuance of the shares referenced above. The Company has also agreed that in the event the Company disposes of the Intellectual Property prior to the periods referenced above, the sellers shall be entitled to the issuance of all the shares referenced above. The Company is in the process of locating a suitable lab to conduct the preclinical trial phase, which has not yet begun as of the date of filing. Placement Agreement On August 8, 2017, the Company entered into an agreement with a third-party placement agent (the “Agent”) who will serve as the Company’s exclusive placement agent or sole book running manager with respect to any offerings of equity or equity-linked securities as well as any debt offering with the two organizations named in the agreement (the “Offering”) for a period of 120 days. In the event that an Offering is agreed upon by the Agent and the Company, the Company shall provide payment as follows: (1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering. In connection with the Company’s November 16, 2017 Note offering, the Agent received a cash commission of $240,000, equal to eight (8%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase eight (8%) percent of the shares of Common Stock issued or issuable in the offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors, or 53,600 shares); however, will receive eight (8%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The Warrants are exercisable six (6) months after the date of issuance, or as of May 16, 2018. In connection with the Company’s September 4, 2018 Note offering, the Agent received a cash commission for this transaction of $140,000, equal to seven (7%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase seven (7%) percent of the shares of Common Stock issued or issuable in this offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors, or 26,056 shares); however, will receive seven (7%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The Warrants are exercisable six (6) months after the date of issuance, or March 4, 2019. Advisory Agreement On April 18, 2018, SkyPharm S.A. entered into a ten-year Advisory Agreement with Synthesis Management Limited (the “Advisor”). The Advisor was retained to assist SkyPharm to secure corporate finance capital. The Advisor shall be paid €104,000 per year during the ten-year term.

EARNINGS PER SHARE

EARNINGS PER SHARE	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 15 - EARNINGS PER SHARE	Basic net income (loss) per share is computed by dividing net income (loss) attributable to the Company, decreased with respect to net income or increased with respect to net loss by dividends declared on preferred stock by using the weighted-average number of common shares outstanding. The dilutive effect of incremental common shares potentially issuable under outstanding options, warrants and restricted shares is included in diluted earnings per share in 2018 and 2017 utilizing the treasury stock method. The computations of basic and diluted per share data were as follows: 12/31/2018 12/31/2017 Numerator for Basic and Diluted Earnings Per Share: Net (loss) income $ (8,842,077 ) $ (6,209,768 ) Denominator for Basic Earnings Per Share: Weighted Average Shares 13,306,612 12,780,813 Potentially Dilutive Common Shares - - Adjusted Weighted Average Shares 13,306,612 12,780,813 Basic and Diluted Net (Loss) Income per Share (0.66 ) (0.49 ) The following table summarized the potential shares of Common Stock that were excluded from the computation of diluted net loss per share for the years ended December 31, 2018 and 2017 as such shares would have had an anti-dilutive effect: 2018 2017 Common Stock Warrants 144,338 38,824 Common Stock Options 60,437 16,240 Convertible Debt 52,381 622,142 Total 257,155 677,206

STOCK OPTIONS AND WARRANTS

STOCK OPTIONS AND WARRANTS	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 16 - STOCK OPTIONS AND WARRANTS	On October 1, 2016 the Company granted 12,000 options to an employee of the Company as compensation for being appointed the US Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $2.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 12,000 options fully vested as of December 31, 2016. The options were valued at $65,290 using the Black Sholes Option Pricing Model with the following inputs: stock price on measurement date: $5.80; Exercise price: $2.00; Option term: 4 years; Computed volatility: 159%. The Company expensed $16,636 as of December 31, 2016. During the year ended December 31, 2017 the Company expensed an additional $48,655. On January 1, 2017 the Company entered into a two-year agreement whereby the employee was granted compensation of €1,000 per month and an annual retainer of 25,000 stock options per year as compensation for being appointed the International Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $1.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly, with a total of 25,000 options fully vested as of December 31, 2017 and December 31, 2018, respectively. The options issued in the year ended December 31, 2017 were valued at $195,307 using the Black Scholes Option Pricing Model with the following inputs: stock price on measurement date: $8.20; Exercise price: $1.00; Option term: 4 years; Computed volatility: 136.76%. The fair value of the options was amortized over a year with $195,307 expensed during the year ended December 31, 2017. The options issued during the year ended December 31, 2017 were valued at $242,002 using the Black Scholes Option Pricing Model with the following inputs: stock price on measurement date: $10.20; Exercise price: $1.00; Option term: 4 years; Computed volatility: 120.92%. The fair value of the options was amortized over a year with $242,002 expensed during the year ended December 31, 2018. On January 3, 2017 the Company determined to create an advisory board and appointed Mr. Orestes Varvitsiotes as its first member. Mr. Varvitsiotes is a registered broker dealer who is currently engaged with Aegis Capital Corp. In connection therewith, the Company entered into an Advisory Board Member Consulting Agreement, dated as of January 3, 2017 whereby an annual retainer of 12,000 stock options was granted as compensation for services. The options have an exercise period of five years with an exercise price of $2.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly, with a total of 12,000 options fully vested as of December 31, 2017. The options were valued at $94,830 using the Black Scholes Option Pricing Model, with the following inputs: stock price on measurement date: $8.20; Exercise price: $2.00; Option term: 5 years; Computed volatility: 155.37%. The fair value of the options was amortized over the year with $94,830 expensed during the year ended December 31, 2017. As of December 31, 2018, there were 74,000 options outstanding and 74,000 options exercisable with expiration dates commencing October 2020 and continuing through January 2022. A summary of the Company’s option activity during the year ended December 31, 2018 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, December 31, 2016 12,000 $ 2.00 3.75 $ - Granted 37,000 1.32 3.33 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2017 49,000 $ 1.49 3.19 $ - Granted 25,000 1.00 4.00 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2017 74,000 $ 1.32 2.47 $ 198,000 Exercisable, December 31, 2017 74,000 $ 1.32 2.47 $ 198,000 In connection with a private placement that took place on April 7, 2017, the Company issued warrants for a total of 10,040 common shares of the Company at a 1:1 ratio for shares purchased by investors. The warrants were valued using the Black Scholes valuation model with stock prices ranging from $7.60 to $8.50, exercise price of $30.00, volatility ranging from 76.66% to 90.86% based on the Company’s stock price, an expected term of 1 year and a risk-free rate ranging from 1.07% to 1.11%. These warrants expired during the year ended December 31, 2018. On November 16, 2017, in connection with the Securities Purchase Agreement, the Company issued warrants for 536,000 common shares of the Company (See Note 16). The fair value of the warrants was determined using a Black Scholes valuation model with a stock price of $7.20, exercise price of $7.50, volatility of 169.29% based on the Company’s stock price, an expected term of 5 years and a risk-free rate of 1.68%. The relative fair value of the warrants of $1,545,288 was recorded as a discount to the Notes and as additional paid in capital and the expense will be amortized over the two-year term of the underlying Notes. The warrants became exercisable on May 16, 2018. On December 12, 2018, in connection with the Third Exchange Agreement (See Note 10), the 536,000 warrants were exchanged for 727,683 warrants. These warrants were immediately exercisable with an exercise price of $6.00 and a termination date of December 11, 2023. On November 16, 2017 in connection with the $3,350,000 Securities Purchase Agreement (See Note 16), Roth Capital Partners, LLC (“Roth”), as the Company’s exclusive placement agent, was issued warrants for 53,600 common shares of the Company. The fair value of the warrants was determined using a Black Scholes valuation model with a stock price of $7.20, exercise price of $5.00, volatility of 169.29% based on the Company’s stock price, an expected term of 5 years and a risk-free rate of 1.68%. The value of the warrants of $368,003 was recognized as interest expense during the year ended December 31, 2017. The warrants became exercisable on May 16, 2018. On September 4, 2018, in connection with the $2,233,333 Securities Purchase Agreement, the Company issued warrants for 357,334 common shares of the Company (See Note 16). The fair value of the warrants was determined using a Black Scholes valuation model with a stock price of $6.40, exercise price of $7.50, volatility of 111.51% based on the Company’s stock price, an expected term of 5 years and a risk free rate of 2.78%. The value of the warrants of $910,078 was recognized as interest expense during the year ended December 31, 2018. The warrants became exercisable on March 4, 2019. On September 4, 2018, in connection with the $2,233,333 Securities Purchase Agreement (See Note 16), Roth Capital Partners, LLC (“Roth”), as the Company’s exclusive placement agent, was issued warrants for 26,056 common shares of the Company. The fair value of the warrants was determined using a Black Scholes valuation model with a stock price of $6.40, exercise price of $5.00, volatility of 169.29% based on the Company’s stock price, an expected term of 5 years and a risk free rate of 2.78%. The value of the warrants of $157,969 was recognized as interest expense during the year ended December 31, 2018. The warrants became exercisable on March 4, 2019. The significant assumptions used to determine the fair values of warrants issued, using a Black-Scholes valuation model are as follows: December 31, 2018 December 31, 2017 Market value of underlying stock $ 6.40 $ 7.20 - $8.50 Volatility 111.51%-254.07 % 76.66% - 169.29 % Expected term (in years) 5 – 5.5 1 - 5.5 Risk-free interest rate 2.77% -2.78 % 1.07% - 1.68 % Expected dividend yield None None A summary of the Company’s warrant activity for the years ending December 31, 2018 and 2017 is as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, December 31, 2016 - $ - - $ - Granted 599,640 7.65 5.29 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2017 599,640 $ 7.65 5.29 $ 1,725,921 Granted 1,111,073 - - - Forfeited (536,000 ) - - - Exercised - - - - Expired (10,040 ) - - - Balance Outstanding, December 31, 2018 1,164,673 $ 6.41 5.01 $ - Exercisable, December 31, 2018 781,283 $ 5.93 4.91 $ -

DISAGGREGATION OF REVENUE

DISAGGREGATION OF REVENUE	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 17 - DISAGGREGATION OF REVENUE	ASC 606-10-50-5 requires that entities disclose disaggregated revenue information in categories (such as type of good or service, geography, market, type of contract, etc). ASC 606-10-55-89 explains that the extent to which an entity’s revenue is disaggregated depends on the facts and circumstances that pertain to the entity’s contracts with customers and that some entities may need to use more than one type of category to meet the objective for disaggregating revenue. The Company disaggregates revenue by country to depict the nature and economic characteristics affecting revenue. The following table presents our revenue disaggregated by country for the years ended: Country December 31, 2018 December 31, 2017 Belgium $ 4,230 $ - Bulgaria - 3,001 Denmark 430,932 1,005,448 France 388,944 168,075 FYROM - 6,003 Germany 14,783,119 14,904,644 Greece 2,970,219 2,034,907 Hungary 1,673,287 - Indonesia 6,449 - Ireland 1,519,746 1,431,638 Italy 481,141 372,166 Jordan 162,749 21,009 Netherlands 3,860,021 4,441,980 Poland 886,218 753,336 Portugal - 6,003 Spain 8,724 - Sweden - 9,004 UK 9,908,103 4,856,165 Total $ 37,083,882 $ 30,013,379

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 18 - SUBSEQUENT EVENTS	Stock Purchase Agreement for the purchase of 193,408 shares of the Company’s common stock On February 5, 2019, Cosmos Holdings Inc. (the “Company”) entered into a Stock Purchase Agreement (the “SPA”) with an institutional noteholder in the Company. The SPA provides for the purchase of 193,408 shares of the Company’s common stock at $3.00 per share or an aggregate of $580,224. Payment is scheduled over a five-month period, subject to acceleration if the Company effects an eligible equity offering (as defined in the agreement). Stock Purchase Agreement for the purchase of 83,341 shares of the Company’s common stock On February 18, 2019, Cosmos Holdings Inc. (the “Company”) entered into a Stock Purchase Agreement (the “SPA”) with an institutional noteholder in the Company. The SPA provides for the purchase of 83,341 shares of the Company’s common stock at $3.00 per share or an aggregate of $250,023. Payment is scheduled over a five-month period, subject to acceleration if the Company effects an eligible equity offering (as defined in the agreement). Senior Promissory Notes executed on April 1 and 3, 2019 On April 1 and 3, 2019, Cosmos Holdings Inc. (the “Company”) executed Senior Promissory Notes (the “Notes”) each in the principal amount of $250,000 payable to an unaffiliated third-party lender. The Notes bear interest at the rate of fifteen (15%) percent per annum, paid quarterly in arrears. The Notes mature on April 1 and 3, 2020 unless prepaid or in default. The Company may prepay the Notes within the first six (6) months by payment of unpaid interest for the first six (6) months interest and after six (6) months, with a (2%) percent ($5,000) premium. The Notes are subject to acceleration in an Event of Default (as defined in the Notes). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the Notes. The guaranty is unconditional and irrevocable, and constitutes a guaranty of performance and of payment when due, and not just of collection. Senior Promissory Note executed on April 9, 2019 On April 9, 2019, Cosmos Holdings Inc. (the “Company”) executed a Senior Promissory Note (the “Note”) in the principal amount of $250,000 payable to an unaffiliated third-party lender who had previously loaned the Company $500,000. The Note bears interest at the rate of fifteen (15%) percent per annum, paid quarterly in arrears. The Note matures on April 9, 2020 unless prepaid or in default. The Company may prepay the Note within the first six (6) months by payment of unpaid interest for the first six (6) months and after six (6) months, with a two (2%) percent ($5,000) premium. The Note is subject to acceleration in an Event of Default (as defined in the Note). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the Note. The guaranty is unconditional and irrevocable, and constitutes a guaranty of performance and of payment when due, and not just of collection.

ORGANIZATION AND NATURE OF BU_2

ORGANIZATION AND NATURE OF BUSINESS (Policies)	12 Months Ended
	Dec. 31, 2018
Organization And Nature Of Business
Basis of Financial Statement Presentation	The accompanying consolidated financial statements have been prepared in accordance with principles generally accepted in the United States of America.
Principles of Consolidation	Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, SkyPharm S.A., Decahedron Ltd. and Cosmofarm Ltd. All significant intercompany balances and transactions have been eliminated.
Use of Estimates	The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2018 and December 31, 2017, there were no cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars and in the Republic of Cyprus, in Greece and in Bulgaria all of which are denominated in Euros. Additionally, the Company maintains a bank account in the United Kingdom denominated in British Pounds. For the year ended December 31, 2018, the amounts in these accounts were $242,903, $203,806 (the Euro equivalent of which was €177,903) and $119,357 (the British Pound equivalent of which was £93,872). At December 31, 2017, the amounts in these accounts were $65,613, $398,841 (the Euro equivalent of which was €331,759) and $27,542 (the British Pound equivalent of which was £20,358). Additionally, for the years ended December 31, 2018 and 2017, the Company had cash on hand in the amount of $166,350 and $290,857, respectively.
Account Receivable	Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. At December 31, 2018 and 2017, the Company's allowance for doubtful accounts was $540,048 and $0, respectively.
Tax Receivables	The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of December 31, 2018 and 2017, the Company had a VAT net receivable balance of $729,790 and $961,220 respectively, recorded in the consolidated balance sheet as other assets.
Inventory	Inventory is stated at the lower of cost or net realizable value using the weighted average cost method. Inventory consists primarily of finished goods and packaging materials, i.e. packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment. The Company writes-down inventories to net realizable value based on physical condition, expiration date, current market conditions, as well as forecasted demand. The Company’s inventories are not highly susceptible to obsolescence. Many of the Company’s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met.
Fixed Assets	Fixed assets are stated at cost, less accumulated depreciation. Depreciation is provided on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Leasehold improvements and technical works 40 years Vehicles 6-20 years Machinery 20 years Furniture, fixtures and equipment 5–10 years Computers and software 3-5 years Depreciation expense was $34,623 and $17,370 for the years ended December 31, 2018 and December 31, 2017, respectively.
Intangible Assets	Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. At December 31, 2018, no revision to the remaining amortization period of the intangible assets was made. Amortization expense was $9,307 and $8,533 for the years ended December 31, 2018 and 2017, respectively.
Impairment of Long-Lived Assets	In accordance with Accounting Standards Codification (“ASC”) 360-10, long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.
Goodwill and Intangibles	The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. Prior to the acquisition of Decahedron, the Company had no recorded goodwill. As a result of the acquisition of Decahedron, the Company tested and impaired 100% of the goodwill allocated to the acquisition costs, an amount equal to $1,949,884 for the year ended December 31, 2017. On December 19, 2018 as a result of the acquisition of Cosmofarm, the Company recorded $49,697 of goodwill. The Company tested the goodwill acquired and determined that no impairment was required as of December 31, 2018.
Equity Method Investment	For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company records its share in the earnings of the investee and is included in “Equity earnings of affiliate” in the consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value.
Investments in Equity Securities	Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01, and accordingly, investments in equity securities are accounted for at fair value with changes in fair value recognized in income from operations. Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for use in current operations are reported as a component of current assets in the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets in the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment. Investments consisted of 40,000 shares which traded at a closing price of $5.27, or value of $210,790 of Diversa S.A. and 16,666 share which traded at a closing price of $0.13 or value of $2,100 of National Bank of Greece. Additionally, the Company has $4,470 in equity securities of Pancreta bank, which are not publicly traded and recorded at cost. See note 5 for additional investments in equity securities.
Fair Value Measurement	The Company applied FASB ASC 820-Fair Value Measurements and Disclosures, or ASC 820, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The following table presents assets that are measured and recognized at fair value as of December 31, 2018, on a recurring basis: December 31, 2018 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities – ICC International Cannabis Corp. $ 2,500,000 - - $ 2,500,000 Marketable securities – Divsersa S.A. 210,790 - - 210,790 Marketable securities – National Bank of Greece 2,100 - - 2,100 $ 2,712,890 $ 2,712,890 The Company did not have any Level 2 or Level 3 assets or liabilities as of December 31, 2018. FASB ASC 825-10-25 Fair Value Option, or ASC 825-10-25, was effective for January 1, 2008. ASC 825-10-25 expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.
Revenue Recognition	The Company adopted the modified retrospective adoption in accordance with ASC 606 – Revenue from Contracts with Customers, on January 1, 2018. The new guidance introduces a five-step model for recognizing revenue by applying the following steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligations are satisfied by transferring the promised goods to the customer. Once these steps are met, revenue is recognized upon delivery of the product. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements.
Stock-based Compensation	The Company records stock-based compensation in accordance with ASC section 718, "Stock Compensation" and Staff Accounting Bulletin (SAB) No. 107 (SAB 107) issued by the SEC in March 2005 regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Merton Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 505-50 "Equity-Based Payments to Non-Employees".
Foreign Currency Translations and Transactions	Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders' equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity's local currency) are included in net earnings.
Concentrations of Credit Risk	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash investments and accounts receivable. The following tables show the number of the Company's clients which contributed 10% or more of revenue and accounts receivable, respectively: Year Ended December 31, Year Ended December 31, 2018 2017 Number of 10% clients 2 3 Percentage of total revenue 26.49 % 49.63 % Percentage of total AR 4.94 % 20.68 %
Income Taxes	The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company is liable for income taxes in Greece and the United Kingdom of England. The corporate income tax rate is 29% in Greece (tax losses are carried forward for five years effective January 1, 2013) and 20% in United Kingdom of England. Losses may also be subject to limitation under certain rules regarding change of ownership. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At December 31, 2018 the Company has maintained a valuation allowance against all net deferred tax assets in each jurisdiction in which it is subject to income tax. The Company periodically reviews the uncertainties and judgments related to the application of complex income tax regulations to determine income tax liabilities in several jurisdictions. The Company uses a “more likely than not” criterion for recognizing the income tax benefit of uncertain tax positions and establishing measurement criteria for income tax benefits. The Company has evaluated the impact of these positions and due to the fact that the fiscal years 2013 - 2014 are unaudited by the Greek tax authorities, a potential tax liability has been identified, which may arise from a prospective tax audit from tax authorities, based on the tax settlement note of years 2007 - 2009. The amount of the liability as of December 31, 2018, was $145,504, and has been recorded as a long-term liability within the balance sheet.
Retirement and Termination Benefits	Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee’s work experience and renumeration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgements related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability. The amount of the liability as of December 31, 2018, was $23,340, and has been recorded as a long-term liability within the balance sheet.
Basic and Diluted Net Income (Loss) per Common Share	Basic income per share is calculated by dividing income available to common shareholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, “Earnings Per Share”, the following table reconciles basic shares outstanding to fully diluted shares outstanding. Years Months Ended December 31, 2018 2017 Weighted average number of common shares outstanding Basic 13,306,612 12,780,013 Potentially dilutive common stock equivalents 257,155 - Weighted average number of common and equivalent shares outstanding - Diluted 13,306,612 12,780,013 Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented.
Recent Accounting Pronouncements	Effective January 1, 2018, the Company adopted ASU 2016-01, “Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” and ASU 2018-03, “Technical Corrections and Improvements to Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.” ASU 2016-01 contained a number of changes which are applicable to the Company including the following: (1) requires equity investments to be measured at fair value with changes in fair value recognized in net income; and (2) allows equity investments without readily determinable fair values to be measured at cost less impairment, if any, plus or minus changes in observable prices (referred to as the “measurement alternative”); ASU 2018-03 also clarified certain aspects of the guidance issued in ASU 2016-01, including requiring a prospective transition approach for equity investments without readily determinable fair value in which the measurement alternative is applied. ASU 2016-01 does not apply to investments accounted for using the equity method, investments in consolidated subsidiaries, FHLB stock, and investments in low income housing tax credit projects. The ASU also eliminated the requirement to classify equity investments into different categories such as “Available-for-sale.” The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350), which simplifies the measurement of goodwill by eliminating Step 2 from the current goodwill impairment test in the event that there is evidence of an impairment based on qualitative or quantitative assessments. ASU 2017-04 does not change how the goodwill impairment is identified, and the Company will continue to perform a qualitative assessment annually to determine whether the two-step impairment test is required. Until the adoption, current accounting standards require the impairment loss to be recognized under Step 2 of the impairment test. This requires the Company to calculate the implied fair value of goodwill by assigning fair value to the reporting unit’s assets and liabilities as if the reporting unit has been acquired in a business combination, then subsequently subtracting the implied goodwill from the carrying amount of the goodwill. The new standard would require the Company to determine the fair value of the reporting unit and subtract the carrying value from the fair value of the reporting unit to determine if there is an impairment. ASU 2017-04 is effective for the Company for fiscal years after December 15, 2019, and early adoption is permitted. ASU 2017-04 is required to be adopted prospectively, and the adoption is effective for annual goodwill impairment tests performed in the year of adoption. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as an acquisition of assets or a business. ASU No. 2017-01 is effective for the Company’s fiscal year commencing on January 1, 2018. The effect of this guidance is to be applied prospectively and early adoption is permitted. The adoption of ASU No. 2017-01 did not have a material effect on the Company’s consolidated financial position or the Company’s consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, “Leases,” which will require lessees to recognize assets and liabilities for the rights and obligations created by most leases on the balance sheet. The changes become effective for the Company’s fiscal year beginning January 1, 2020. Modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, is required with an option to use certain transition relief. The Company expects this ASU will increase its current assets and current liabilities, but have no net material impact on its consolidated financial statements. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company's financial statements.

ORGANIZATION AND NATURE OF BU_3

ORGANIZATION AND NATURE OF BUSINESS (Tables)	12 Months Ended
	Dec. 31, 2018
Organization Nature Of Business And Going Concern Tables Abstract
Schedule of Calculation of Fixed Assets	Estimated Useful Life Leasehold improvements and technical works 40 years Vehicles 6-20 years Machinery 20 years Furniture, fixtures and equipment 5–10 years Computers and software 3-5 years
Schedule of measured and recognized at fair value	December 31, 2018 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities – ICC International Cannabis Corp. $ 2,500,000 - - $ 2,500,000 Marketable securities – Divsersa S.A. 210,790 - - 210,790 Marketable securities – National Bank of Greece 2,100 - - 2,100 $ 2,712,890 $ 2,712,890
Schedule of Concentrations of Credit Risk	Year Ended December 31, Year Ended December 31, 2018 2017 Number of 10% clients 2 3 Percentage of total revenue 26.49 % 49.63 % Percentage of total AR 4.94 % 20.68 %
Schedule of reconciles basic and diluted shares outstanding.	Years Months Ended December 31, 2018 2017 Weighted average number of common shares outstanding Basic 13,306,612 12,780,013 Potentially dilutive common stock equivalents 257,155 - Weighted average number of common and equivalent shares outstanding - Diluted 13,306,612 12,780,013

ACQUISITION OF DECAHEDRON, LTD

ACQUISITION OF DECAHEDRON, LTD (Tables)	12 Months Ended
	Dec. 31, 2018
Acquisition Of Decahedron Ltd
Unaudited allocation of purchase price	Preliminary Allocation as of February 10, Allocation Final 2017 Adjustments Allocation Current assets $ 6,537 $ - $ 6,537 Intangible assets 50,000 - 50,000 Other assets 305,400 (216,562 ) 88,838 Total assets acquired 361,937 (216,562 ) 145,375 Liabilities assumed: Debt 804,819 (188,560 ) 616,259 Total liabilities assumed 804,819 (188,560 ) 616,259 Net assets acquired (442,882 ) (28,002 ) (470,884 ) Consideration: Value of Common Stock Issued at Acquisition 1,479,000 - 1,479,000 Goodwill $ 1,921,882 $ 28,002 $ 1,949,884
Intangible assets	Amount Useful Life (Years) Licenses (a) $ 50,000 5 $ 50,000 -
Unaudited Supplemental Pro Forma Data	Years Ended December 31, 2018 2017 Revenues $ 37,083,882 $ 30,206,825 Cost of revenues 34,675,242 28,256,544 Gross profit 2,408,640 1,950,281 Operating expenses 3,637,062 6,856,585 Operating loss (1,228,422 ) (4,906,304 ) Other income (expense) (7,814,910 ) (1,372,288 ) Income tax (expense) (17,326 ) (2,801 ) Net Loss $ (9,060,658 ) $ (6,281,393 ) Other comprehensive gain (loss) 1,418,018 (343,766 ) Comprehensive net loss $ (7,642,601 ) $ (6,616,159 )

ACQUISITION OF COSMOFARM, LTD (

ACQUISITION OF COSMOFARM, LTD (Tables)	12 Months Ended
	Dec. 31, 2018
Acquisition Of Cosmofarm Ltd
Schedule of purchase price of Cosmofarm	Allocation Current assets $ 6,882,286 Intangible assets 213,790 Other assets 1,519,345 Total assets acquired 8,615,421 Liabilities assumed: Accounts payable and other current liabilities 5,111,489 Advances from customers 1,192,600 Line of credit 1,900,388 Other liabilities 232,729 Total liabilities assumed 8,437,206 Net assets acquired 178,215 Consideration: Promissory note 227,912 Goodwill $ 49,697
Schedule of acquired intangible assets	Amount Useful Life (Years) Trademark $ 36,997 5 Customer base 176,793 10 $ 213,790 -

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2018
Property Plant And Equipment
Schedule of property plant and equipment	2018 2017 Leasehold Improvements $ 369,437 $ 3,098 Equipment under capital lease 709,356 - Vehicles 117,402 3,805 Furniture, fixtures and equipment 458,442 107,520 Computers and software 55,169 20,072 1,709,806 134,495 Less: Accumulated depreciation (284,174 ) (19,928 ) Total $ 1,425,632 $ 114,567

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2018
Intangible Assets Tables Abstract
Schedule of Intangible assets	2018 2017 License $ 50,000 $ 50,000 Trade Name / Mark 36,997 - Customer Base 124,686 - 211,683 50,000 Less: Accumulated Amortization (16,720 ) (8,006 ) Total $ 194,963 $ 41,994

CAPITAL STRUCTURE (Tables)

CAPITAL STRUCTURE (Tables)	12 Months Ended
	Dec. 31, 2018
Capital Structure
Schedule of other assets and other liabilities	December 31, 2018 Cash and cash equivalents $ 683 Accounts receivable 13,421 Accounts payable and accrued expenses (8,775 ) Loans payable - related party (9,501 ) Taxes payable (1,423,674 ) Accumulated other comprehensive loss 1,287,010 Total liabilities extinguished (140,836 ) Proceeds due from sale of subsidiary (5,811 ) Gain on sale of Amplerissimo $ (146,647 )

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2018
Income Taxes Tables Abstract
Schedule of reconciliation of income tax expense	12/31/2018 12/31/2017 US Income before income taxes $ (8,731,677 ) $ (6,209,768 ) Taxes under statutory US tax rates $ (1,833,652 ) $ (2,111,321 ) Increase (decrease) in taxes resulting from: Increase (decrease) in valuation allowance $ 554,452 $ 156,724 Foreign tax rate differential $ 164,394 $ 424,810 Tax Cuts and Jobs Act $ - $ 181,881 Permanent differences $ 1,628,906 $ 1,384,635 Purchase price adjustments $ 25,202 $ - Discrete items $ (318,892 ) $ - State taxes $ (146,148 ) $ (31,629 ) Income tax (expense) benefit $ 74,263 $ 5,100
Schedule of deferred tax assets and liabilities	12/31/2018 12/31/2017 Net Operating Loss Carryforward $ 904,877 $ 514,338 Nonqualified Stock Options 187,513 - Depreciation 1,602 - Total Deferred tax assets 1,093,992 514,338 Intangibles (10,729 ) - Goodwill (14,473 ) - Total Deferred tax liabilities (25,202 ) - Valuation allowance (1,068,790 ) (514,338 ) Net deferred tax assets (liabilities) $ - $ -

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments And Contingencies
Schedule of future minimum operating lease commitments	Year Ended December 31, Amount (USD) 2019 $ 207,853 2020 $ 118,054 2021 $ 70,121 2022 $ 45,824 2023 $ 45,824 Thereafter $ 164,203 $ 651,879
Schedule of future minimum lease payments	Year Ending December 31, Amount (USD) 2019 36,801 2020 14,955 Less amount representing interest (2,217 ) Present value of minimum lease payments 49,539 Less current portion (34,805 ) 14,734

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2018
Earnings Per Share
Schedule of Earnings Per Share, Basic and Diluted	12/31/2018 12/31/2017 Numerator for Basic and Diluted Earnings Per Share: Net (loss) income $ (8,842,077 ) $ (6,209,768 ) Denominator for Basic Earnings Per Share: Weighted Average Shares 13,306,612 12,780,813 Potentially Dilutive Common Shares - - Adjusted Weighted Average Shares 13,306,612 12,780,813 Basic and Diluted Net (Loss) Income per Share (0.66 ) (0.49 )
Schedule of potentially anti-dilutive shares of Common Stock	2018 2017 Common Stock Warrants 144,338 38,824 Common Stock Options 60,437 16,240 Convertible Debt 52,381 622,142 Total 257,155 677,206

STOCK OPTIONS AND WARRANTS (Tab

STOCK OPTIONS AND WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2018
Stock Options And Warrants
Schedule of option activity during the year	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, December 31, 2016 12,000 $ 2.00 3.75 $ - Granted 37,000 1.32 3.33 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2017 49,000 $ 1.49 3.19 $ - Granted 25,000 1.00 4.00 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2017 74,000 $ 1.32 2.47 $ 198,000 Exercisable, December 31, 2017 74,000 $ 1.32 2.47 $ 198,000
Warrants activity valued	December 31, 2018 December 31, 2017 Market value of underlying stock $ 6.40 $ 7.20 - $8.50 Volatility 111.51%-254.07 % 76.66% - 169.29 % Expected term (in years) 5 – 5.5 1 - 5.5 Risk-free interest rate 2.77% -2.78 % 1.07% - 1.68 % Expected dividend yield None None
Warrants	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, December 31, 2016 - $ - - $ - Granted 599,640 7.65 5.29 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2017 599,640 $ 7.65 5.29 $ 1,725,921 Granted 1,111,073 - - - Forfeited (536,000 ) - - - Exercised - - - - Expired (10,040 ) - - - Balance Outstanding, December 31, 2018 1,164,673 $ 6.41 5.01 $ - Exercisable, December 31, 2018 781,283 $ 5.93 4.91 $ -

DISAGGREGATION OF REVENUE (Tabl

DISAGGREGATION OF REVENUE (Tables)	12 Months Ended
	Dec. 31, 2018
Disaggregation Of Revenue
Schedule of revenue disaggregated by country	Country December 31, 2018 December 31, 2017 Belgium $ 4,230 $ - Bulgaria - 3,001 Denmark 430,932 1,005,448 France 388,944 168,075 FYROM - 6,003 Germany 14,783,119 14,904,644 Greece 2,970,219 2,034,907 Hungary 1,673,287 - Indonesia 6,449 - Ireland 1,519,746 1,431,638 Italy 481,141 372,166 Jordan 162,749 21,009 Netherlands 3,860,021 4,441,980 Poland 886,218 753,336 Portugal - 6,003 Spain 8,724 - Sweden - 9,004 UK 9,908,103 4,856,165 Total $ 37,083,882 $ 30,013,379

ORGANIZATION AND NATURE OF BU_4

ORGANIZATION AND NATURE OF BUSINESS (Details)	12 Months Ended
	Dec. 31, 2018
Furniture and Fixtures [Member]
Estimated Useful Life	40 years
Vehicles [Member] | Minimum [Member]
Estimated Useful Life	6 years
Vehicles [Member] | Maximum [Member]
Estimated Useful Life	20 years
Machinery [Member]
Estimated Useful Life	20 years
Furniture, fixtures and equipment [Member] | Minimum [Member]
Estimated Useful Life	5 years
Furniture, fixtures and equipment [Member] | Maximum [Member]
Estimated Useful Life	10 years
Computers and software [Member] | Minimum [Member]
Estimated Useful Life	3 years
Computers and software [Member] | Maximum [Member]
Estimated Useful Life	5 years

ORGANIZATION AND NATURE OF BU_5

ORGANIZATION AND NATURE OF BUSINESS (Details 1)	Dec. 31, 2018USD ($)
Fair value of assets and liabilities	$ 2,712,890
Level 1 [Member]
Fair value of assets and liabilities	2,712,890
Level 2 [Member]
Fair value of assets and liabilities
Level 3 [Member]
Fair value of assets and liabilities
Marketable securities - ICC International Cannabis Corp. [Member]
Fair value of assets and liabilities	2,500,000
Marketable securities - ICC International Cannabis Corp. [Member] | Level 1 [Member]
Fair value of assets and liabilities	2,500,000
Marketable securities - ICC International Cannabis Corp. [Member] | Level 2 [Member]
Fair value of assets and liabilities
Marketable securities - ICC International Cannabis Corp. [Member] | Level 3 [Member]
Fair value of assets and liabilities
Marketable securities - Divsersa S.A. [Member]
Fair value of assets and liabilities	210,790
Marketable securities - Divsersa S.A. [Member] | Level 1 [Member]
Fair value of assets and liabilities	210,790
Marketable securities - Divsersa S.A. [Member] | Level 2 [Member]
Fair value of assets and liabilities
Marketable securities - Divsersa S.A. [Member] | Level 3 [Member]
Fair value of assets and liabilities
Marketable securities - National Bank of Greece [Member]
Fair value of assets and liabilities	2,100
Marketable securities - National Bank of Greece [Member] | Level 1 [Member]
Fair value of assets and liabilities	2,100
Marketable securities - National Bank of Greece [Member] | Level 2 [Member]
Fair value of assets and liabilities
Marketable securities - National Bank of Greece [Member] | Level 3 [Member]
Fair value of assets and liabilities

ORGANIZATION AND NATURE OF BU_6

ORGANIZATION AND NATURE OF BUSINESS (Details 2) - Integer	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Organization And Nature Of Business Details 2Abstract
Number of 10% clients	2	3
Percentage of total revenue	26.49%	49.63%
Percentage of total AR	4.94%	20.68%

ORGANIZATION AND NATURE OF BU_7

ORGANIZATION AND NATURE OF BUSINESS (Details 3) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Organization And Nature Of Business Details Abstract
Weighted average number of common shares outstanding Basic	13,306,612	12,780,013
Potentially dilutive common stock equivalents	257,155	677,206
Weighted average number of common and equivalent shares outstanding - Diluted	13,306,612	12,780,013

ORGANIZATION, NATURE OF BUSINES

ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 21, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 19, 2018	Sep. 30, 2018	Sep. 29, 2018	Feb. 10, 2017	Sep. 27, 2013
State or country of incorporation		Nevada
Date of incorporation		Jul. 21, 2009
Reverse stock split, description	the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of Common Stock.
Revenue		$ 37,083,882	$ 30,013,379
Cost of revenue		34,675,242	28,057,111
Net loss		(9,060,658)	(6,209,768)
Working capital deficit		(3,927,074)
Accumulated deficit		(16,272,645)	(7,211,987)
Cash equivalents		166,350	290,857
Allowance for doubtful accounts		540,048	0
Value added tax receivable		961,220	729,790
Depreciation expense		$ 34,623	17,370
Description for periodic inventory system maintenance		A periodic inventory system is maintained by 100% count.
Intangible assets, useful life		5 years
Amortization of intangible assets		$ 9,307	8,533
Impairment of goodwill		$ 0	$ 1,949,884
Impairment of goodwill, percent		100.00%	100.00%
Goodwill		$ (14,473)		$ 49,697
Net cash used in operations		(1,555,305)	(8,760,141)
Long-term liability		145,504
Potential retirement and termination benefits liability		$ 23,340
National Bank of Greece [Member]
Equity method investment shares acquired, shares		16,666
Equity method investment shares acquired, value		$ 2,100
Closing price		$ 0.13
Diversa S.A. [Member]
Equity method investment shares acquired, shares		40,000
Equity method investment shares acquired, value		$ 210,790
Closing price		$ 5.27
Amplerissimo Ltd [Member]
Equity ownership percentage								100.00%
Ownership interest sold					100.00%
SkyPharm [Member]
Equity ownership percentage						100.00%
Percentage of ownership interest transferred to company by Amplerissimo						22.00%
Decahedron Ltd [Member] | Stock Purchase Agreement [Member]
Common stock shares reserved							170,000
United Kingdom of England [Member]
Income tax rate		20.00%
Greece [Member]
Income tax rate		29.00%
United Kingdom [Member]
Cash equivalents		$ 119,357	27,542
Cyprus Greece And Bulgaria [Member]
Cash equivalents		203,806	398,841
United States [Member]
Cash equivalents		$ 242,903	$ 65,613

ACQUISITION OF DECAHEDRON, LT_2

ACQUISITION OF DECAHEDRON, LTD. (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Intangible assets	$ 50,000
Consideration:
Goodwill	$ 213,790
Decahedron Ltd [Member] | Preliminary Allocation as of February 10, 2017 [Member]
Current assets		$ 6,537
Intangible assets		50,000
Other assets		305,400
Total assets acquired		361,937
Liabilities assumed:
Debt		804,819
Total liabilities assumed		804,819
Net assets acquired		(442,882)
Consideration:
Value of Common Stock Issued at Acquisition		1,479,000
Goodwill		1,921,882
Decahedron Ltd [Member] | Allocation Adjustments [Member]
Current assets
Intangible assets
Other assets		(216,562)
Total assets acquired		(216,562)
Liabilities assumed:
Debt		(188,560)
Total liabilities assumed		(188,560)
Net assets acquired		(28,002)
Consideration:
Value of Common Stock Issued at Acquisition
Goodwill		28,002
Decahedron Ltd [Member] | Final Allocation [Member]
Current assets		6,537
Intangible assets		50,000
Other assets		88,838
Total assets acquired		145,375
Liabilities assumed:
Debt		616,259
Total liabilities assumed		616,259
Net assets acquired		(470,884)
Consideration:
Value of Common Stock Issued at Acquisition		1,479,000
Goodwill		$ 1,949,884

ACQUISITION OF DECAHEDRON, LT_3

ACQUISITION OF DECAHEDRON, LTD. (Details 1)	12 Months Ended
	Dec. 31, 2018USD ($)
Intangible assets	$ 50,000
Useful Life (Years)	5 years
Licenses [Member]
Intangible assets	$ 50,000	[1]
[1]	(a) U.K Pharmaceutical Wholesale Distribution License

ACQUISITION OF DECAHEDRON, LT_4

ACQUISITION OF DECAHEDRON, LTD. (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cost of revenues	$ 34,675,242	$ 28,057,111
Gross profit	2,408,640	1,956,267
Operating expenses	3,637,062	6,828,588
Operating loss	(1,228,422)	(4,872,321)
Income tax (expense)	17,326	2,801
Other comprehensive loss	(7,642,601)	(6,544,534)
Decahedron Ltd [Member] | Proforma [Member]
Revenues	37,083,882	30,206,825
Cost of revenues	34,675,242	28,256,544
Gross profit	2,408,640	1,950,281
Operating expenses	3,637,062	6,856,585
Operating loss	(1,228,422)	(4,906,304)
Other income (expense)	(7,814,910)	(1,372,288)
Income tax (expense)	(17,326)	(2,801)
Net Loss	(9,060,658)	(6,281,393)
Other comprehensive loss	1,418,018	(343,766)
Comprehensive net loss	$ (7,642,601)	$ (6,616,159)

ACQUISITION OF DECAHEDRON, LT_5

ACQUISITION OF DECAHEDRON, LTD. (Details Narrative)	12 Months Ended
	Dec. 31, 2018USD ($)Integershares	Dec. 31, 2017USD ($)
Business acquisition, name of acquired entity	DECAHEDRON, LTD
Business acquisition outstanding percentage	100.00%
Number of businesses acquired | Integer	1
Business acquisition outstanding shares value	$ 1,479,000
Business acquisition outstanding shares in exchange | shares	170,000
Adjustment related to other assets and accounts payable		$ 28,002
Impairment of goodwill	$ 0	$ 1,949,884
Impairment of goodwill, percent	100.00%	100.00%
Cash acquired on acquisition	$ 40,858
Acquisition [Member]
Revenues		$ 4,221,751
Net Loss		$ 441,553

ACQUISITION OF COSMOFARM, LTD.

ACQUISITION OF COSMOFARM, LTD. (Details) - USD ($)	Dec. 31, 2018	Dec. 19, 2018	Dec. 31, 2017
Current assets	$ 18,347,162		$ 9,510,526
Intangible assets	296,767		41,994
Other assets	624,479		1,008,579
Total assets acquired	20,694,953		10,675,666
Liabilities assumed:
Advances from customers	1,067,200
Line of credit	1,514,583
Other liabilities	183,577
Total liabilities assumed	24,012,403		13,703,510
Promissory note	2,919,286
Goodwill	(14,473)	$ 49,697
Allocation [Member]
Current assets	6,882,286
Intangible assets	213,790
Other assets	1,519,345
Total assets acquired	8,615,421
Liabilities assumed:
Accounts payable and other current liabilities	5,111,489
Advances from customers	1,192,600
Line of credit	1,900,388
Other liabilities	232,729
Total liabilities assumed	8,437,206
Net assets acquired	178,215
Promissory note	227,912
Goodwill	$ 49,697

ACQUISITION OF COSMOFARM, LTD_2

ACQUISITION OF COSMOFARM, LTD. (Details 1)	12 Months Ended
	Dec. 31, 2018USD ($)
Acquired intangible assets	$ 213,790
Acquired intangible assets, Useful Life (Years)	5 years
Trademark [Member]
Acquired intangible assets	$ 36,997
Acquired intangible assets, Useful Life (Years)	5 years
Customer base [Member]
Acquired intangible assets	$ 176,793
Acquired intangible assets, Useful Life (Years)	10 years

ACQUISITION OF COSMOFARM, LTD_3

ACQUISITION OF COSMOFARM, LTD. (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 19, 2018
Cash received from acquisition	$ 307,590	$ 40,858
Business acquisition outstanding percentage	100.00%
Cosmofarm SPA [Member]
Business acquisition outstanding percentage			100.00%

PREPAID FINANCING COSTS (Detail

PREPAID FINANCING COSTS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Deferred financing costs		$ 0
Mr. Spyros Papadopoulos [Member]
Advisory fees paid	$ 706,044
Synthesis Management Limited [Member]
Advisory fees paid	214,344
Synthesis Multi-Asset Architecture [Member]
Advisory fees paid	$ 217,406

INVESTMENTS (Details Narrative)

INVESTMENTS (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 16, 2018	Dec. 31, 2018	May 17, 2018
Equity interest acquired, percentage		100.00%
Gain on exchange of equity investments, net of unrealized loss on change in fair value		$ 2,500,000
Unrealized gain on exchange of investment		1,545,200
Cash received with accounting associated		2,000,000
Kaneh Bosm Biotechnology Inc [Member] | Share Exchange Agreement [Member]
Transfer of shares			2,500,000
Kaneh Bosm Biotechnology Inc [Member] | Share Exchange Agreement [Member] | Canadian Securities Exchange [Member]
Exchange of shares			5,000,000
ICC [Member] | Share exchange agreement [Member]
Equity method investment shares acquired	5,000,000
Description for ownership percentage	The ten million shares of ICC owned by the Company constitute approximately 7% of the 141,219,108 shares of capital stock of KBB then issued and outstanding
Marathon Global Inc [Member]
Gain on exchange of investment		$ 1,953,000
Marathon Global Inc [Member] | Share exchange agreement [Member]
Shares of Marathon transferred by company to KBB	2,500,000
Gain on exchange of investment	$ 2,092,200
Marathon Global Inc [Member] | Distribution and Equity Acquisition Agreement [Member]
Equity interest acquired, percentage		33.33%
Cash received upon repayment for purchase common stock		$ 2,000,000
Sale of stock, number of shares issued for distribution services		5,000,000
Marathon Global Inc [Member] | Distribution and Equity Acquisition Agreement [Member] | Gross Sales One [Member]
Cash received upon gross sales		$ 2,750,000
Gross sales		13,000,000
Marathon Global Inc [Member] | Distribution and Equity Acquisition Agreement [Member] | Gross Sales [Member]
Cash received upon gross sales		2,750,000
Gross sales		$ 6,500,000

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property plant and equipment	$ 1,709,806	$ 134,495
Less: Accumulated depreciation	(284,174)	(19,928)
Total	1,425,632	114,567
Computers and software [Member]
Property plant and equipment	55,169	20,072
Equipment under capital lease [Member]
Property plant and equipment	709,356
Leasehold Improvements [Member]
Property plant and equipment	369,437	3,098
Vehicles [Member]
Property plant and equipment	117,402	3,805
Furniture, fixtures and equipment [Member]
Property plant and equipment	$ 458,442	$ 107,520

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Leasing Arrangement [Member]
Machinery and equipment	$ 193,034
Capital Leases [Member]
Accumulated amortization	$ 38,607	$ 0

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Intangible assets	$ 211,683	$ 50,000
Less: Accumulated Amortization	(16,720)	(8,006)
Total	194,963	41,994
Trade Name / Mark [Member]
Intangible assets	36,997
Customer Base [Member]
Intangible assets	124,686
License [Member]
Intangible assets	$ 50,000	$ 50,000

CAPITAL STRUCTURE (Details)

CAPITAL STRUCTURE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash and cash equivalents	$ 864,343	$ 782,853	$ 716,590
Accounts receivable	4,753,291	1,255,596
Accounts payable and accrued expenses	5,933,464	1,778,333
Loans payable - related party	1,775,251	7,213
Taxes payable		1,358,789
Accumulated other comprehensive loss	32,828	(1,385,229)
Proceeds due from sale of subsidiary	5,811
Amplerissimo [Member]
Cash and cash equivalents	683
Accounts receivable	13,421
Accounts payable and accrued expenses	(8,775)
Loans payable - related party	(9,501)
Taxes payable	(1,423,674)
Accumulated other comprehensive loss	1,287,010
Total liabilities extinguished	(140,836)
Proceeds due from sale of subsidiary	(5,811)
Gain on sale of Amplerissimo	$ (146,647)

CAPITAL STRUCTURE (Details Narr

CAPITAL STRUCTURE (Details Narrative) - USD ($)	Oct. 02, 2017	Apr. 10, 2017	Apr. 07, 2017	Mar. 01, 2017	Nov. 30, 2018	Sep. 29, 2018	Jun. 18, 2018	Dec. 19, 2017	Nov. 21, 2017	Jul. 21, 2017	May 25, 2017	May 18, 2017	May 16, 2017	Apr. 26, 2017	May 25, 2017	May 24, 2017	Dec. 31, 2018	Dec. 31, 2017	Feb. 10, 2017
Common stock, shares issued																	13,878,772	12,825,393
Common stock, shares outstanding																	13,705,082	12,666,704
Common stock shares authorized																	300,000,000	300,000,000
Preferred stock shares authorized																	100,000,000	100,000,000
Common stock value																	$ 13,879	$ 12,825
Reverse stock split, description									the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of Common Stock.
Purchase of treasury stock from officer																	(129,612)	(94,495)
Related party accrual for repurchase of shares of common stock																	48,683	61,422
Revenue																	37,083,882	30,013,379
Tranche 3 [Member]
Purchase of treasury stock from officer																	11,317
Due to related party																	48,683
Stock Purchase Agreement [Member] | Third Party Investor [Member]
Purchase of treasury stock, Shares	138,689
Purchase of treasury stock from officer	$ 1,387
Tranche 2 [Member]
Purchase of treasury stock from officer																	69,178
Gain/Loss of change in foreign currency																	434
Tranche 1 [Member]
Purchase of treasury stock from officer																	63,446
Gain/Loss of change in foreign currency																	$ 2,024
Tranche [Member]
Purchase of treasury stock from officer																		33,073
Related party accrual for repurchase of shares of common stock																		$ 61,422
Prior to merger [Member]
Common stock, shares issued																	10,000,000
Prior to merger [Member] | Amplerissimo Ltd [Member]
Common stock, shares issued																	2,558,553
Director [Member] | Stock Purchase Agreement [Member]
Purchase of treasury stock, Shares					20,000		15,000	20,000
Purchase of treasury stock from officer					$ 60,000		$ 69,612	$ 94,495
Potentially dilutive securities [Member] | Employee [Member] | On January 1, 2018 [Member]
Stock options granted																	25,000
Exercise period																	4 years
Exercise price																	$ 1
Stock options vested																	25,000
Potentially dilutive securities [Member] | Employee [Member] | On January 3, 2017 [Member]
Stock options granted																	12,000
Exercise period																	5 years
Exercise price																	$ 2
Stock options vested																	12,000
Potentially dilutive securities [Member] | Employee [Member] | On January 1, 2017 [Member]
Stock options granted																	25,000
Exercise period																	4 years
Exercise price																	$ 1
Stock options vested																	25,000
Potentially dilutive securities [Member] | Private Placement [Member]
Stock options granted			5,000
Common stock value			$ 35,000
Stock options granted fair value			$ 35,000
Investor [Member] | Subscription Arrangement [Member]
Stock options granted		4,580											790	4,670
Price per share		$ 7								$ 5			$ 7	$ 7
Common stock value		$ 32,060								$ 21,500			$ 5,530	$ 32,690
Common Stock Shares Subscribed		4,580								4,300			790	4,670
Stock options granted fair value		$ 2,375											$ 130	$ 1,521
ArKo European Business & Services [Member] | Consulting agreement Four [Member]
Common stock, shares issued											20,000				20,000
Commencing agreement date											May 25, 2017
Consulting agreement period											20 months
Common stock value											$ 154,000				$ 154,000
Price per share											$ 7.70				$ 7.70
Consultant charges											$ 56,138
Consulting expense yet to be recognized											$ 92,299				$ 92,299
ArKo European Business & Services [Member] | Consulting agreement Three [Member]
Common stock, shares issued												30,000
Commencing agreement date												May 8, 2017
Consulting agreement period												1 year
Common stock value												$ 219,000
Monthly consultant charges												$ 5,000
ArKo European Business & Services [Member] | Consulting Agreement Two [Member]
Common stock, shares issued											2,000				2,000
Commencing agreement date															May 1, 2017
Consulting agreement period															5 months
Common stock value											$ 14,400				$ 14,400
Price per share											$ 7.20				$ 7.20
ArKo European Business & Services [Member] | Consulting Agreement one [Member]
Common stock, shares issued																2,000
Commencing agreement date																May 1, 2017
Commencing terminating date																Jan. 1, 2018
Consulting agreement period																8 months
Common stock value																$ 14,400
ArKo European Business & Services [Member] | Consulting Agreement [Member]
Restricted shares of common stock				500
Consulting agreement period				4 months
Decahedron Ltd [Member] | Stock Purchase Agreement [Member]
Common stock shares reserved																			170,000
Amplerissimo Ltd [Member] | Fiscal 2018 [Member]
Revenue																	$ 7,639,022
Amplerissimo Ltd [Member] | Fiscal 2018 [Member] | Share purchase agreement [Member]
Purchase price																	5,811
Gain on sale of Amplerissimo																	$ 146,647
SkyPharm [Member]
Purchase price						$ 2,528
Ownership percentage						100.00%
Percentage of ownership interest transferred to company by amplerissimo						22.00%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Taxes Details Abstract
Income before income taxes	$ (8,731,677)	$ (6,209,768)
Taxes under statutory US tax rates	(1,833,652)	(2,111,321)
Increase (decrease) in taxes resulting from:
Increase (decrease) in valuation allowance	554,452	156,724
Foreign tax rate differential	164,394	424,810
Tax Cuts and Jobs Act		181,881
Permanent differences	1,628,906	1,384,635
Purchase price adjustments	25,202
Discrete items	(318,892)
State taxes	(146,148)	(31,629)
Income tax (expense) benefit	$ 74,263	$ 5,100

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2018	Dec. 19, 2018	Dec. 31, 2017
Income Taxes Details 1Abstract
Net operating loss carry forward	$ 904,877		$ 514,338
Nonqualified Stock Options	187,513
Depreciation	1,602
Total Deferred tax assets	1,093,992		514,338
Intangibles	(10,729)
Goodwill	(14,473)	$ 49,697
Total Deferred tax liabilities	(25,202)
Valuation allowance	1,068,790		(514,338)
Net deferred tax assets (liabilities)

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 22, 2018	Dec. 31, 2018	Dec. 31, 2017
Federal Statutory Income Tax Rate, description	corporate tax rate from 35 percent to 21 percent, effective January 1, 2018 and the establishment of a territorial-style system for taxing foreign-source income of domestic multinational corporations.	subject to limitation under IRC Section 382. Of the $2.4 million, of Federal net operating loss carryforwards, $2.2 million begin to expire in 2031. The remaining balance of $.2 million is limited in annual usage of 80% of current year
Reduction in net deferred tax assets			$ 181,881
Net operating loss carry forward		$ 2,400,000
Federal [Member]
Net operating loss carry forward		2,200,000
United States [Member]
Net operating loss carry forward		$ 2,422,876
Expiry		2031
United Kingdom [Member]
Net operating loss carry forward		$ 847,896
Greece [Member]
Net operating loss carry forward		$ 847,896
Expiry		2019

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Nov. 04, 2015	Nov. 30, 2018	Jun. 18, 2018	Dec. 19, 2017	Nov. 21, 2014	Dec. 31, 2018	Dec. 20, 2018	Dec. 31, 2017	Dec. 20, 2017	Dec. 31, 2016	Sep. 30, 2018	Jul. 22, 2009
Aggregate forgiveness of related party notes						$ 47,717
Shares issued						13,878,772		12,825,393
Debt outstanding amount						$ 1,514,583
Repayment of related party debt						631,166		978,730
Revenue						37,083,882		30,013,379
Accounts receivable balance						4,753,291		1,255,596
Purchase of treasury stock from officer						(129,612)		(94,495)
Officers and directors [Member]
Shares issued												2,000,000
Dimitrios Goulielmos [Member]
Aggregate forgiveness of related party notes	$ 142,860
Debt instrument decrease accrued interest forgiveness	806
Due to related party	$ 200,000				$ 401,115
Debt outstanding amount						61,290
Repayment of related party debt								84,755		$ 63,312
Interest rate					2.00%
Maturity date					May 11, 2015
Accrued interest						0
Konstantinos Vassilopoulos [Member]
Prepaid balance						0
Net prepaid balance						369		369
Debt outstanding amount						9,810
Paid in existing bills								10,179
Borrowing						168,000
Accrued interest						0
Ourania Matsouki [Member]
Prepaid balance						34,368
Due to related party								66,121		47,479
Repayment of related party debt								120,214
Borrowing						34,368
Grigorios Siokas [Member]
Prepaid balance						1,550,799	$ 1,718,400
Repayment of loans						317,877
Borrowing						1,917,545	$ 1,718,400
Interest rate							4.70%
Maturity date							Mar. 18, 2019
Accrued interest							$ 63,371
Total compensation amount							$ 0		$ 250,000
Grigorios Siokas [Member] | Loan payable [Member]
Due to related party								749,717		$ 95,496
Debt outstanding amount								858,516
Grigorios Siokas One [Member]
Prepaid balance						227,000
Repayment of loans						155,000
Borrowing						382,000
MediHelm S.A. [Member]
Prepaid balance						2,817,953
Net prepaid balance						2,764,387
Accounts payable balance						53,566
Accounts receivable balance						145,826
SkyPharm [Member]
Accrued interest						526,656
SkyPharm [Member] | MediHelm S.A. [Member]
Payments to acquire businesses						11,302,842		10,202,135
Revenue						1,247,208		1,429,784
DOC Pharma S.A. [Member]
Prepaid balance						2,139,109		933,425
Net prepaid balance						2,103,006		772,623
Accounts payable balance						36,103		160,801
Payments to acquire businesses						5,431,361		5,349,187
Revenue						238,284		0
On October 1, 2016 [Member] | Grigorios Siokas [Member]
Prepaid balance											$ 0
Due to related party						5,276
Debt outstanding amount											6,973
Short term debt, borrowing capacity						$ 1,202
Maturity date						Oct. 1, 2017
Accrued interest											$ 0
MediHelm S.A. [Member] | Dimitrios Goulielmos [Member]
Due to related party						$ 233,118
Decahedron [Member] | MediHelm S.A. [Member]
Payments to acquire businesses						958,454		784,272
Stock Purchase Agreement [Member] | Director [Member]
Due to related party						0
Consideration amount paid						70,902
Purchase of treasury stock from officer		$ 60,000	$ 69,612	$ 94,495
Purchase of treasury stock, Shares		20,000	15,000	20,000
Stock Purchase Agreement [Member] | Director [Member] | November 30, 2018 [Member]
Due to related party						48,683
Consideration amount paid						11,317
Tranche 1 [Member]
Due to related party						0
Repayment of loans						61,448
Purchase of treasury stock from officer						63,446
Tranche [Member]
Purchase of treasury stock from officer								$ 33,073
Loan agreement [Member] | DOC Pharma S.A. [Member]
Debt outstanding amount						13,474
Accrued interest						836
Loan agreement [Member] | On November 1, 2015 [Member] | DOC Pharma S.A. [Member]
Short term debt, borrowing capacity						12,662
Payment of miscellaneous bills						$ 12,662
Interest rate						2.00%
Maturity date						Oct. 31, 2016

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative) - USD ($)	Dec. 13, 2018	Dec. 12, 2018	Sep. 04, 2018	Feb. 20, 2018	Feb. 19, 2018	Nov. 15, 2017	Dec. 31, 2018	Dec. 31, 2017	Apr. 24, 2018
Convertible notes payable, principal amount							$ 2,919,286
Common stock, par value							$ 0.001	$ 0.001
Debt discount							$ 3,169,672	$ 3,350,000
Fair Value of Warrants							157,969	368,003
Debt outstanding amount							1,514,583
Amortization of debt discount					$ 392,272		3,124,058	360,890
Purchase price of financing cost							25,202
Beneficial conversion feature							386,062
Loss on extinguishment of debt							(1,464,698)
Outstanding principal balance							$ 149,938
Dividend yield
Related Party Debt							$ 2,408,965	$ 817,040
Third Amendment and Exchange Agreements [Member]
Exercise price		$ 6
Warrants retired		536,000
Warrants [Member] | Securities Purchase Agreement [Member]
Common stock shares issuable upon conversion of debt/convertible securities			357,334	536,000		536,000
Common stock, par value			$ 6			$ 5
Proceeds from issuance of warrants						$ 2,686,000
Legal fees						$ 74,000
Debt instrument maturity date			Mar. 1, 2019
Maturity period			5 years	5 years		5 years
Warrants exercise price				$ 7.50		$ 7.50
Fair Value of Warrants			$ 910,078	$ 1,545,288
Terms of Blocker Provision			The Notes or the Warrants, into shares of common stock if its beneficial ownership of the common stock would exceed 9.99% of the Company’s issued and outstanding common stock (a “Blocker”).	A blocker provision which prevents any holder from converting or exercising, as applicable, the Notes or the Warrants, into shares of Common Stock if its beneficial ownership of the Common Stock would exceed 4.99% (subject to adjustment not to exceed 9.99%) of the Company’s issued and outstanding Common Stock (each, a “Blocker”).
Conditional proceeds from sale of common stock under the agreement			$ 20,000
Debt original issue discount			$ 233,332
Amortization of interest expense				$ 347,418
Debt convertible conversion description			The Notes and Warrants on any trading day to not more than such Buyer’s pro rata allocation of the greater of (x) sales with net proceeds of an aggregate of $20,000 or (y) twenty-five (25%) percent of the daily average trading volume of the Company’s Common Stock. If after the closing of the Financing the VWAP of the Company’s common stock for three (3) trading days is less than $1.50 per share, the Company may further restrict the Buyers from selling at less than $1.50 per share
Exercise price			$ 7.50
Roth Capital Partners, LLC [Member] | Placement agent [Member]
Proceeds from issuance of warrants			$ 140,000
Debt instrument maturity date			Mar. 4, 2019
Maturity period			5 years
Fair Value of Warrants			$ 157,969
Terms of Blocker Provision			will receive seven (7%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months.
Roth Capital Partners, LLC [Member] | Placement agent [Member] | Warrants [Member]
Common stock shares issuable upon conversion of debt/convertible securities			26,056
Warrants exercise price			$ 6
Debt original issue discount			$ 140,000
November 15, 2017 Securities Purchase Agreement [Member] | Third Amendment and Exchange Agreements [Member]
Debt instrument maturity date		Dec. 11, 2023
Warrants issued		727,683
September 4, 2018 Securities Purchase Agreement [Member] | Third Amendment and Exchange Agreements [Member]
Related Party Debt		$ 1,333,333
Conversion price		$ 3.478
Debt modification expense	$ 1,778,952
Common stock issued	383,363
Leak-out Agreement [Member] | Warrants [Member] | Securities Purchase Agreement [Member]
Convertible notes payable, principal amount						$ 3,350,000
Debt discount								240,000
Fair Value of Warrants								$ 386,003
Terms of agreement				As a condition to the closing of the Financing, each Buyer, severally, was required to execute a leak-out agreement (each, a “Leak-Out Agreement”) restricting such Buyer’s sale of shares of Common Stock underlying the Notes and Warrants on any Trading Day to not more than such Buyer’s pro rata allocation of the greater of (x) sales with net proceeds of an aggregate of $20,000 or (y) twenty-five (25%) percent of the daily average trading volume of the Company’s Common Stock. If after the closing of the Financing there is no Event of Default under the Notes, the VWAP of the Company’s Common Stock for three (3) trading days is less than $1.50 per share, the Company may further restrict the Buyers from selling at less than $1.50 per share; provided that the portion of the Notes subject to redemption on each Installment Date shall thereafter double.
Conditional proceeds from sale of common stock under the agreement				$ 20,000
Terms of commission to placement agent						Placement agent, received a cash commission for the transaction equal to eight (8%) percent of the total gross proceeds of the offering, or $240,000 and the issuance of five-year warrants to purchase eight (8%) percent of the shares of common stock issued or issuable in this offering (excluding shares of common stock issuable upon exercise of any warrants issued to investors), or 53,600 shares; and, will receive eight (8%) percent of any cash proceeds received from the exercise of any warrants sold in the offering with an expiration equal to or less than twenty-four (24) months.
Post-modification [Member] | Third Amendment and Exchange Agreements [Member]
Exercise price		$ 6
Fair value of common stock		$ 6
Expected volatility		113.62%
Dividend yield		0.00%
Risk-free rate		2.77%
Expected life		5 years
Pre-modification [Member] | Third Amendment and Exchange Agreements [Member]
Exercise price		$ 7.50
Fair value of common stock		$ 6
Expected volatility		243.69%
Dividend yield		0.00%
Risk-free rate		2.77%
Expected life		3 years 11 months 4 days
Registration Rights Agreement [Member] | Warrants [Member] | Securities Purchase Agreement [Member]
Debt instrument maturity date				Feb. 1, 2019
Terms of agreement				The Company filed, within thirty (30) days of the Closing, a registration statement covering one hundred fifty (150%) percent of the maximum number of shares, underlying the Notes and Warrants pursuant to a registration rights agreement with the Buyers (the “Registration Rights Agreement”).
September 2018 Notes [Member] | Holder [Member] | Warrants [Member] | Securities Purchase Agreement [Member]
Common stock, par value			$ 6
Event of default conversion price, description			Upon an Event of Default (regardless of whether such event has been cured), the Buyers may convert at an alternative conversion price equal to the lower of the then applicable Conversion Price or seventy-five (75%) percent of the then Volume-Weighted Average Price (as defined, the “VWAP”).
Debt instrument maturity date			Nov. 1, 2018
Customary events of default, description			The Notes at a redemption premium of one hundred twenty-five (125%) percent, multiplied by the greater of the conversion rate and the then current market price. The Buyers may also require redemption of the Notes upon a Change of Control (as defined) at a premium of one hundred twenty-five (125%) percent. The Company has the right to redeem the Notes at any time, in whole or in part, in cash at a price equal to 120% of the then outstanding conversion amount.
Debt original issue discount			$ 934,922
Per-delivery shares issued			372,222
September 2018 Notes [Member] | Institutional investors [Member] | Securities Purchase Agreement [Member]
Convertible notes payable, principal amount			$ 2,233,333
Common stock shares issuable upon conversion of debt/convertible securities			372,222
Common stock, par value			$ 0.001
Proceeds from issuance of warrants			$ 1,845,000
Legal fees			$ 15,000
Debt instrument maturity date			May 1, 2019
Purchase price charged to financing costs			$ 140,000
Purchase price of financing cost			$ 2,000,000
Exercise price			$ 7.50
Convertible Notes [Member]
Debt discount							2,233,332
Amortization of debt discount							2,049,232
Beneficial conversion feature							1,333,333
Outstanding principal balance							$ 261,903
Conversion price							$ 3.478
Convertible Notes [Member] | Third Exchange Agreement [Member]
Convertible notes payable, principal amount							$ 638,095
Convertible Notes [Member] | September 2018 [Member]
Event of Default Interest rate							18.00%
Installment fees							$ 31,905
Interest Rate							5.00%
New Notes [Member] | Exchange Agreements [Member]
Convertible notes payable, principal amount				$ 3,216,000
Debt discount				3,216,000	1,140,711
Amortization of debt discount					$ 405,743
Debt original issue discount				336,000
Beneficial conversion feature				2,880,000
Loss on extinguishment of debt				1,464,698
Adjustments to beneficial conversion feature and issue of debt discount				1,739,289
Senior Convertible Notes [Member] | Securities Purchase Agreement [Member]
Common stock shares issuable upon conversion of debt/convertible securities						670,000
Common stock, par value						$ 0.001
Debt original issue discount						$ 350,000
Purchase price charged to financing costs						240,000
Purchase price of financing cost						3,000,000
Senior Convertible Notes [Member] | Exchange Agreements [Member]
Convertible notes payable, principal amount				$ 2,871,429
Common stock, par value				$ 5
Convertible debt, description				The Company evaluated the debt modification in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment as the 10% cash flow test was met.
Event of default conversion price, description				Upon an Event of Default (as defined), the Buyers may convert at an alternative conversion price equal to the lower of the then applicable Conversion Price or seventy-five (75%) percent of the Volume-Weighted Average Price (as defined, the “VWAP”).
Debt discount				$ 2,596,838
Customary events of default, description				The Notes include customary Events of Default and provide that the Buyers may require the Company to redeem (regardless of whether the Event of Default has been cured) all or a portion of the Notes at a redemption premium of one hundred twenty-five (125%) percent, multiplied by the greater of the conversion rate and the then current market price. The Buyers may also require redemption of the Notes upon a Change of Control (as defined) at a premium of one hundred twenty-five (125%) percent.
Existing note description				(i) the New Note was not convertible into shares of the Company’s common stock (the “Common Stock”) until April 20, 2018; (ii) all future cash installment payments under such New Note will be made at a redemption price equal to 112% of the applicable installment amount; (iii) the Company’s existing obligation to initially deliver pre-delivery shares of its common stock to the holder of such New Note was deferred until April 20, 2018; and (iv) at any time on or before June 20, 2018, the Company had the right, at its option, to redeem all, or any part, of the amounts then outstanding under such New Note in cash at a redemption price equal to 125% of such amounts then outstanding under such New Note.
Cash proceeds received by holders				85.00%
Additional paid in capital				$ 1,140,711
Aggregate indebtedness				$ 12,000,000
Per-delivery shares issued									670,001
Senior Convertible Note 2 [Member] | Institutional investors [Member] | Securities Purchase Agreement [Member]
Convertible notes payable, principal amount						3,350,000
Senior Convertible Note 1 [Member] | Institutional investors [Member] | Securities Purchase Agreement [Member]
Convertible notes payable, principal amount						$ 3,000,000

DEBT (Details Narrative)

DEBT (Details Narrative) - USD ($)

Apr. 02, 2018

May 12, 2017

May 05, 2017

Apr. 10, 2017

Mar. 16, 2017

Aug. 04, 2016

May 04, 2016

Mar. 04, 2016

Feb. 05, 2016

Nov. 05, 2015

Mar. 04, 2015

Oct. 17, 2018

May 31, 2018

Mar. 16, 2018

Feb. 19, 2018

Jan. 18, 2018

May 16, 2017

Mar. 23, 2017

Mar. 20, 2017

Dec. 31, 2016

Oct. 18, 2016

May 24, 2016

Apr. 22, 2016

Apr. 19, 2016

Nov. 16, 2015

Dec. 31, 2018

Dec. 20, 2018

Dec. 31, 2017

Dec. 31, 2016

Mar. 31, 2018

Nov. 16, 2017

Jul. 31, 2017

Jan. 31, 2017

Nov. 30, 2016

Oct. 31, 2016

Sep. 30, 2016

Sep. 13, 2016

Dec. 31, 2015

Debt outstanding amount

$ 1,514,583

Debt discount

3,169,672

3,350,000

Amortization of debt discount

$ 392,272

3,124,058

360,890

Cash received

$ 40,858

CEO [Member]

Percentage of wholly-owned subsidiary shares

51.00%

TFF [Member]

Short term debt borrowing capacity

$ 15,000,000

Libor rate description

(i) all lending in U.S. dollars is the one-month LIBOR plus six (6%) percent margin; and (ii) for all lending in Euro, the one-month Euribor Rate plus six (6%) percent per annum, commencing June 1, 2018

On April 18, 2018 [Member]

Maturity date

Dec. 31, 2021

Debt outstanding amount

$ 3,078,442

Accrued interest

$ 14,830

Libor rate description

Additionally the interest rate was amended such that the interest rate for all advances is 4% plus the 3-Month Libor rate

Gain on debt settlement

$ 23,354

Loan Facility July 6, 2017 [Member]

Fees forgiven related to advance

40,000

Loan Agreement 2 [Member]

Short term debt borrowing capacity

$ 21,812

$ 1,718,400

Interest rate

1.00%

4.70%

Maturity date

Nov. 5, 2016

Mar. 18, 2019

Debt outstanding amount

1,718,400

12,022

Accrued interest

63,371

138

Repayment of debt

$ 2,110

11,456

9,618

Proceeds from debt

10,906

Loan Facility Agreement [Member]

Debt discount

191,034

Amortization of debt discount

56,043

Unamortized debt discount

20,237

Total amortized

$ 114,158

Loan Agreement 3 [Member]

Short term debt borrowing capacity

$ 6,144

$ 87,248

Interest rate

4.70%

5.00%

Maturity date

Nov. 5, 2016

Debt outstanding amount

68,588

$ 68,588

Accrued interest

4,087

Repayment of debt

66,121

Proceeds from debt

76,342

Repayments of accounts receivable

12,022

Loan Agreement 1 [Member]

Short term debt borrowing capacity

$ 91,785

Interest rate

6.50%

Maturity date

Jan. 17, 2019

Marathon [Member]

Distribution and equity acquisition agreement, description

As consideration for its services, Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company's distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in Common Shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company's receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000

Settlement amount

$ 1,554,590

Cash received

$ 2,000,000

Shares issued for settlement of debt

337,158

Loan Agreement 6 [Member]

Short term debt borrowing capacity

$ 21,104

Interest rate

6.00%

Accrued interest

1,226

Repayment of debt

24,044

Loan Agreement 7 [Member]

Short term debt borrowing capacity

$ 57,430

$ 55,050

Interest rate

6.00%

Maturity date

May 4, 2017

Mar. 4, 2017

Accrued interest

1,413

Repayment of debt

120,220

Loan Agreement 10 [Member]

Short term debt borrowing capacity

$ 55,725

Interest rate

6.00%

Maturity date

May 24, 2017

Accrued interest

1,533

Repayment of debt

60,110

Loan Agreement 9 [Member]

Short term debt borrowing capacity

$ 42,708

Interest rate

6.00%

Maturity date

Apr. 22, 2017

Accrued interest

2,136

Repayment of debt

45,684

Loan Agreement 8 [Member]

Short term debt borrowing capacity

$ 113,750

Interest rate

6.00%

Maturity date

Apr. 19, 2017

Accrued interest

3,727

Repayment of debt

120,220

Loan Agreement 11 [Member]

Short term debt borrowing capacity

$ 10,997

Interest rate

10.00%

Maturity date

Oct. 18, 2017

Accrued interest

655

Repayment of debt

12,022

Panagiotis Drakopoulos [Member] | Loan Agreement [Member]

Short term debt borrowing capacity

$ 42,832

Interest rate

6.00%

Maturity date

Nov. 15, 2016

Debt outstanding amount

$ 14,893

20,437

Accrued interest

3,538

2,477

Panagiotis Drakopoulos [Member] | Loan Agreement 5 [Member]

Short term debt borrowing capacity

$ 32,718

Repayment of debt

20,437

13,718

SkyPharm [Member]

Accrued interest

526,656

SkyPharm [Member] | MediHelm S.A. [Member]

Amortization of debt discount

66,226

69,269

Monthly fees

376,082

Origination fees

137,063

125,435

SkyPharm [Member] | Bridge Loans [Member]

Short term debt borrowing capacity

$ 34,745

$ 50,000

$ 120,220

Interest rate

10.00%

10.00%

10.00%

Maturity date

Sep. 30, 2017

Apr. 16, 2017

Apr. 20, 2017

Amended maturity date

May 16, 2017

May 20, 2017

Debt outstanding amount

$ 50,000

$ 106,542

34,745

Accrued interest

$ 14,138

16,857

3,906

Gain on debt settlement

19,695

Additional gain on settlement of debt

4,668

Loan fixed payoff amount

$ 106,542

SkyPharm [Member] | Loan Facility Agreement [Member]

Short term debt borrowing capacity

$ 1,292,769

Interest rate

10.00%

Description for the repayment

The amounts owed under the Loan Facility shall be repayable upon the earlier of (i) three months following the demand of the lender; or (ii) August 31, 2018. No prepayment is permitted pursuant to the terms of the Loan Facility

SkyPharm [Member] | Second amendment to loan facility agreement [Member]

Short term debt borrowing capacity

$ 2,664,960

452,471

70,000

452,471

$ 382,327

$ 155,516

$ 250,000

$ 100,000

$ 174,000

Interest rate

10.00%

Maturity date

Aug. 4, 2016

Debt outstanding amount

3,117,287

Accrued interest

221,657

Description for the repayment

The amounts owed under the Loan Facility shall be repayable upon the earlier of (i) seventy five days following the demand of the Lender; or (ii) August 31, 2018

Common stock shares issuable upon conversion of debt/convertible securities

1,000,000

Debt discount

$ 126,624

42,149

$ 126,624

SkyPharm [Member] | Amendment to loan facility agreement [Member]

Short term debt borrowing capacity

$ 1,533,020

Debt outstanding amount

$ 240,251

Grigorios Siokas [Member]

Interest rate

4.70%

Accrued interest

$ 63,371

Grigorios Siokas [Member] | Loan Agreement 2 [Member]

Note payable transferred to related party

$ 1,718,400

Grigorios Siokas [Member] | Loan Agreement 1 [Member]

Debt outstanding amount

92,400

Accrued interest

2,002

Grigorios Siokas [Member] | Synthesis facility agreement [Member] | Loan Facility Agreement [Member]

Common stock shares issuable upon conversion of debt/convertible securities

10,000,000

Angelo Drakopoulos [Member] | Loan Agreement 1 [Member]

Short term debt borrowing capacity

$ 9,000

Interest rate

8.00%

Maturity date

May 5, 2016

Debt outstanding amount

9,000

Accrued interest

$ 1,463

TFF [Member] | Synthesis facility agreement [Member]

Debt outstanding amount

$ 5,629,555

Accrued interest

$ 524,094

Description for amendment to agreement under ASU 470-50

The Company evaluated the amended agreement under ASC 470-50 and concluded that it did not meet the 10% cash flow test and recorded debt modification expense of $138,110

Debt modification expense

$ 138,110

TFF [Member] | Synthesis facility agreement [Member] | Principal balance 1 [Member]

Maturity date

Aug. 31, 2021

Accrued interest

0

Debt split, balance

$ 2,000,000

2,291,200

Interest rate description

6% per annum plus one-month Euribor, when it is positive, on the Euro balance

Repayment of debt, periodic payments

$ 125,000

Frequency of periodic payments

Quarterly

TFF [Member] | Synthesis facility agreement [Member] | Principal balance 2 [Member]

Maturity date

Aug. 31, 2021

Accrued interest

19,834

Debt split, balance

$ 4,000,000

$ 4,000,000

Interest rate description

6% per annum plus one month Libor on the USD balance

Repayment of debt, periodic payments

$ 150,000

Frequency of periodic payments

Quarterly

Trade Facility Agreements [Member]

Debt outstanding amount

$ 5,866,910

Payment of interest and principal

$ 1,123,600

Trade Facility Agreements [Member] | SkyPharm [Member]

Short term debt borrowing capacity

$ 2,291,200

Debt outstanding amount

$ 5,369,678

Description for the repayment

The total facility will be calculated as 95% of the agreed upon value of Decahedrons receivables.

Term of credit facility

12 months

Credit facility origination fee, percentage

2.00%

Monthly credit fee, percentage

1.00%

Additional gain on settlement of debt

$ 332,640

Maximum aggregate amount supplement deed

$ 18,480,000

Proceeds from debt

$ 247,117

Trade Facility Agreements [Member] | SkyPharm [Member] | Minimum [Member]

Short term debt borrowing capacity

$ 2,291,200

Trade Facility Agreements [Member] | SkyPharm [Member] | Maximum [Member]

Short term debt borrowing capacity

$ 6,873,600

Trade Facility Agreements [Member] | SkyPharm [Member] | Decahedron [Member]

Short term debt borrowing capacity

$ 3,150,400

Description for the repayment

The total facility will be calculated as 95% of the agreed upon value of Decahedrons receivables

Term of credit facility

12 months

Credit facility origination fee, percentage

2.00%

Monthly credit fee, percentage

1.00%

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2018USD ($)
Note 9.Commitments And Contingencies Details Abstract
2019	$ 207,853
2020	118,054
2021	70,121
2022	45,824
2023	45,824
Thereafter	164,203
Total	$ 651,879

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details 1)	Dec. 31, 2018USD ($)
Commitments And Contingencies Details 1Abstract
2019	$ 36,801
2020	14,955
Less amount representing interest	(2,217)
Present value of minimum lease payments	49,539
Less current portion	(34,805)
Total	$ 14,734

COMMITMENTS AND CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)

Sep. 04, 2018

Aug. 08, 2017

Nov. 16, 2017

May 31, 2017

Oct. 25, 2016

Jun. 30, 2016

May 31, 2016

Dec. 31, 2015

Jan. 31, 2015

Sep. 30, 2014

Dec. 31, 2018

Dec. 31, 2017

Operating lease periodic payment

$ 709

Frequency of periodic payment

Monthly

Lease, interest expense

$ (967,824)

$ (748,474)

Operating lease rental expense

$ 8,651

8,502

Operating lease expiration date

May 31, 2017

Lease agreement description

The Company has negotiated and entered into a two-year amendment to that lease that commenced as of June 1, 2017 through May 31, 2019. The monthly rate from June 1, 2017 through May 31, 2018 was $709 per month and increased to $730 per month from June 1, 2018 through May 31, 2019.

Capital Lease [Member]

Lease, interest expense

$ 256

$ 0

Decahedron [Member]

Operating lease periodic payment

$ 2,430

Frequency of periodic payment

Monthly

Monthly

Operating lease rental expense

$ 39,762

$ 27,180

Operating lease expiration date

Oct. 24, 2021

SkyPharm [Member]

Operating lease periodic payment

$ 1,432

$ 4,955

Frequency of periodic payment

Monthly

Monthly

Term of operating lease

6 years

SkyPharm [Member] | MediHelm S.A. [Member]

Operating lease rental expense

$ 127,624

116,400

Total monthly operating lease amount

10,310

SkyPharm [Member] | Additional space [Member]

Operating lease periodic payment

$ 2,091

$ 916

Frequency of periodic payment

Monthly

Monthly

SkyPharm [Member] | First Floor [Member]

Operating lease periodic payment

$ 916

Frequency of periodic payment

Monthly

SkyPharm [Member] | April 18, 2018 [Member] | Advisory Agreement [Member]

Term of operating lease

10 years

Annually operating lease amount

$ 104,000

Amplerissimo [Member]

Operating lease periodic payment

$ 110

Frequency of periodic payment

Monthly

Operating lease rental expense

$ 1,183

$ 1,492

Operating lease renewal date

Jul. 31, 2018

Cosmofarm [Member]

Frequency of periodic payment

Monthly

Operating lease rental expense

$ 1,654

Operating lease expiration date

Sep. 30, 2018

Term of operating lease

10 years

Total monthly operating lease amount

$ 3,809

Neos Kosmos [Member]

Frequency of periodic payment

Monthly

Operating lease rental expense

$ 457

Operating lease expiration date

May 1, 2017

Term of operating lease

3 years

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member]

Operating lease periodic payment

$ 1,500

Common stock shares reserved

200,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member] | Conclusion of Preclinical Trials [Member]

Common stock shares reserved

50,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member] | conclusion of Phase I testing [Member]

Common stock shares reserved

50,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member] | Conclusion of Phase III testing [Member]

Common stock shares reserved

50,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member] | Conclusion of Phase II testing [Member]

Common stock shares reserved

50,000

Private Placement [Member]

Commitments and contingencies description

(1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering.

Cash commission description

In connection with the Company’s September 4, 2018 Note offering, the Agent received a cash commission for this transaction of $140,000, equal to seven (7%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase seven (7%) percent of the shares of Common Stock issued or issuable in this offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors, or 26,056 shares); however, will receive seven (7%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The Warrants are exercisable six (6) months after the date of issuance, or March 4, 2019.

In connection with the Company’s November 16, 2017 Note offering, the Agent received a cash commission of $240,000, equal to eight (8%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase eight (8%) percent of the shares of Common Stock issued or issuable in the offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors, or 53,600 shares); however, will receive eight (8%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The Warrants are exercisable six (6) months after the date of issuance, or as of May 16, 2018.

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Numerator for Basic and Diluted Earnings Per Share:
Net (loss) income	$ (9,060,658)	$ (6,209,768)
Weighted Average Shares	13,306,612	12,780,013
Potentially Dilutive Common Shares
Adjusted Weighted Average Shares	13,306,612	12,780,813
Basic and Diluted Net (Loss) Income per Share	$ (0.66)	$ (0.49)

EARNINGS PER SHARE (Details 1)

EARNINGS PER SHARE (Details 1) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Excluded from computation of diluted net loss per share	257,155	677,206
Convertible Debt [Member]
Excluded from computation of diluted net loss per share	52,381	622,142
Warrants [Member]
Excluded from computation of diluted net loss per share	144,338	38,824
Options [Member]
Excluded from computation of diluted net loss per share	60,437	16,240

STOCK OPTIONS AND WARRANTS (Det

STOCK OPTIONS AND WARRANTS (Details) - Options [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Number of Shares Outstanding, Beginning	49,000	12,000
Granted	25,000	37,000
Forfeited
Exercised
Expired
Number of Shares Outstanding, Ending	74,000	49,000
Number of Shares Exercisable	74,000
Weighted Average Exercise Price
Weighted Average Exercise Price Outstanding, Beginning	$ 1.49	$ 2
Granted	1	1.32
Forfeited
Exercised
Expired
Weighted Average Exercise Price Outstanding, Ending	1.32	$ 1.49
Weighted Average Exercise Price Exercisable	$ 1.32
Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term Outstanding, Beginning	3 years 2 months 8 days	3 years 9 months
Granted	4 years	3 years 3 months 29 days
Weighted Average Remaining Contractual Term Outstanding, Ending	2 years 5 months 20 days	3 years 2 months 8 days
Weighted Average Remaining Contractual Term Exercisable	2 years 5 months 20 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding, Beginning
Granted
Forfeited
Exercised
Expired
Aggregate Intrinsic Value Outstanding, Ending	198,000
Aggregate Intrinsic Value Exercisable	$ 198,000

STOCK OPTIONS AND WARRANTS (D_2

STOCK OPTIONS AND WARRANTS (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Market value of underlying stock	$ 6.40
Expected dividend yield
Minimum [Member]
Market value of underlying stock		$ 7.20
Volatility	111.51%	76.66%
Expected term (in years)	5 years	1 year
Risk-free interest rate	2.77%	1.07%
Maximum [Member]
Market value of underlying stock		$ 8.50
Volatility	254.07%	169.29%
Expected term (in years)	5 years 6 months	5 years 6 months
Risk-free interest rate	2.78%	1.68%

STOCK OPTIONS AND WARRANTS (D_3

STOCK OPTIONS AND WARRANTS (Details 2) - Warrants [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Number of Shares Outstanding, Beginning	599,640
Granted	1,111,073	599,640
Forfeited	(536,000)
Exercised
Expired	(10,040)
Number of Shares Outstanding, Ending	1,164,673	599,640
Number of Shares Exercisable	781,283
Weighted Average Exercise Price
Weighted Average Exercise Price Outstanding, Beginning	$ 7.65
Granted		7.65
Forfeited
Exercised
Expired
Weighted Average Exercise Price Outstanding, Ending	6.41	$ 7.65
Weighted Average Exercise Price Exercisable	$ 5.93
Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term Outstanding, Beginning	5 years 3 months 15 days
Granted		5 years 3 months 15 days
Weighted Average Remaining Contractual Term Outstanding, Ending	5 years 4 days	5 years 3 months 15 days
Weighted Average Remaining Contractual Term Exercisable	4 years 10 months 28 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding, Beginning	$ 1,725,921
Granted
Forfeited
Exercised
Expired
Aggregate Intrinsic Value Outstanding, Ending		1,725,921
Aggregate Intrinsic Value Exercisable

STOCK OPTIONS AND WARRANTS (D_4

STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)	Dec. 12, 2018	Sep. 04, 2018	Apr. 07, 2017	Nov. 16, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Interest expenses					$ 1,942,156
Stock Option [Member] | Mr. Orestes Varvitsiotes [member] | January 3, 2017 [Member]
Stock options granted					12,000
Exercise period					5 years
Exercise price					$ 2
Stock options/warrants value					$ 94,830
Stock price						$ 8.20
Exercise price						$ 2
Option/warrant term						5 years
Volatility rate						155.37%
Stock option periodic vesting						12,000
Stock Option [Member] | Employee [Member] | January 1, 2017 [Member]
Stock price						$ 8.20
Exercise price						$ 1
Stock option periodic vesting						25,000
Stock Option [Member] | Employee [Member] | On January 1, 2017 [Member]
Exercise period					4 years
Exercise price					$ 1
Stock options/warrants value					$ 242,002	$ 195,307
Stock price					$ 10.20
Exercise price					$ 1
Option/warrant term					4 years	4 years
Volatility rate					120.92%	136.76%
Stock option periodic vesting					25,000
Frequency of periodic vesting					Monthly
Consideration under agreement					$ 1,000
Share based compensation as annual retainer					25,000
Stock Option [Member] | Employee [Member] | On October 1, 2016 [Member]
Stock price					$ 5.80
Exercise price					$ 2
Stock Option [Member] | International Finance Manager [Member]
Amortization expense					$ 242,002	$ 195,307
Stock Option [Member] | US Finance Manager [Member]
Amortization expense						48,655	$ 16,636
Stock option periodic vesting							12,000
Stock Option [Member] | US Finance Manager [Member] | On October 1, 2016 [Member]
Stock options granted					12,000
Exercise period					4 years
Exercise price					$ 2
Stock options/warrants value					$ 65,290
Option/warrant term					4 years
Volatility rate					159.00%
Frequency of periodic vesting					Monthly
Stock Option [Member] | Aegis capital corp [Member]
Amortization expense						$ 94,830
Maximum [Member]
Option/warrant term					5 years 6 months	5 years 6 months
Volatility rate					254.07%	169.29%
Risk-free interest rate					2.78%	1.68%
Minimum [Member]
Option/warrant term					5 years	1 year
Volatility rate					111.51%	76.66%
Risk-free interest rate					2.77%	1.07%
Securities Purchase Agreement [Member] | Roth Capital Partners, LLC [Member]
Common stock value issuable under agreement				$ 3,350,000
Warrants [Member]
Exercise price						$ 7.65
Number of Shares Outstanding					1,164,673	599,640
Number of Shares Exercisable					781,283
Warrants [Member] | Private Placement [Member]
Exercise price			$ 30
Option/warrant term			1 year
Warrants issued ratio description			1:1 ratio for shares
Common stock shares reserved			10,040
Warrants [Member] | Private Placement [Member] | Maximum [Member]
Stock price			$ 8.50
Volatility rate			90.86%
Risk-free interest rate			1.11%
Warrants [Member] | Private Placement [Member] | Minimum [Member]
Stock price			$ 7.60
Volatility rate			76.66%
Risk-free interest rate			1.07%
Warrants [Member] | Securities Purchase Agreement [Member]
Stock options/warrants value				$ 1,545,288
Stock price		$ 6.40		$ 7.20
Exercise price		$ 7.50		$ 7.50
Option/warrant term		5 years		5 years
Volatility rate		111.51%		169.29%
Common stock shares reserved		357,334		536,000
Risk-free interest rate		2.78%		1.68%
Amortization period				2 years
Common stock value issuable under agreement		$ 2,233,333
Warrants exercisable period		Mar. 4, 2019		May 16, 2018
Exchange agreement description	the 536,000 warrants were exchanged for 727,683 warrants. These warrants were immediately exercisable with an exercise price of $6.00 and a termination date of December 11, 2023.
Interest expenses					$ 910,078
Warrants [Member] | Securities Purchase Agreement [Member] | Roth Capital Partners, LLC [Member]
Stock options/warrants value				$ 368,003
Stock price		$ 6.40		$ 7.20
Exercise price		$ 5		$ 5
Option/warrant term		5 years		5 years
Volatility rate		169.29%		169.29%
Common stock shares reserved		26,056		53,600
Risk-free interest rate		2.78%		1.68%
Common stock value issuable under agreement		$ 2,233,333
Warrants exercisable period		Mar. 4, 2019		May 16, 2018
Interest expenses					$ 157,969
Options [Member]
Exercise price					$ 1	$ 1.32
Number of Shares Outstanding					74,000	49,000	12,000
Number of Shares Exercisable					74,000

DISAGGREGATION OF REVENUE (Deta

DISAGGREGATION OF REVENUE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue	$ 37,083,882	$ 30,013,379
Belgium [Member]
Revenue	4,230
Bulgaria [Member]
Revenue		3,001
Denmark [Member]
Revenue	430,932	1,005,448
France [Member]
Revenue	388,944	168,075
FYROM [Member]
Revenue		6,003
Germany [Member]
Revenue	14,783,119	14,904,644
Greece [Member]
Revenue	2,970,219	2,034,907
Hungary [Member]
Revenue	1,673,287
Indonesia [Member]
Revenue	6,449
Ireland [Member]
Revenue	1,519,746	1,431,638
Italy [Member]
Revenue	481,141	372,166
Jordan [Member]
Revenue	162,749	21,009
Netherlands [Member]
Revenue	3,860,021	4,441,980
Poland [Member]
Revenue	886,218	753,336
Portugal [Member]
Revenue		6,003
Spain [Member]
Revenue	8,724
Sweden [Member]
Revenue		9,004
UK [Member]
Revenue	$ 9,908,103	$ 4,856,165

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Feb. 18, 2019	Feb. 05, 2019	Dec. 31, 2017
Convertible notes payable, principal amount	$ 2,919,286
Common stock, per share	$ 0.001			$ 0.001
Subsequent Event [Member] | Stock Purchase Agreement [Member]
Convertible notes payable, principal amount		$ 250,023	$ 580,224
Common stock shares issuable upon conversion of debt		83,341	193,408
Common stock, per share		$ 3	$ 3
Subsequent Event [Member] | Senior Promissory Notes [Member] | On April 9, 2019 [Member]
Convertible notes payable, principal amount	$ 250,000
Interest rate	15.00%
Maturity date, description	The Note matures on April 9, 2020 unless prepaid or in default.
Description for the payment of installments	The Company may prepay the Note within the first six (6) months by payment of unpaid interest for the first six (6) months and after six (6) months, with a two (2%) percent ($5,000) premium.
Loans payable	$ 500,000
Subsequent Event [Member] | Senior Promissory Notes [Member] | On April 1 and 3, 2019 [Member]
Convertible notes payable, principal amount	$ 250,000
Interest rate	15.00%
Maturity date, description	The Notes mature on April 1 and 3, 2020 unless prepaid or in default.
Description for the payment of installments	The Company may prepay the Notes within the first six (6) months by payment of unpaid interest for the first six (6) months interest and after six (6) months, with a (2%) percent ($5,000) premium.